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ABSTRACT OF DISSERTATION

MOLECULAR AND FUNCTIONAL INVESTIGATION OF CANCER-TYPE AND LIVERTYPE VARIANTS OF ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3
OATP1B3 belongs to the OATP (organic anion transporting polypeptides) superfamily,
responsible for mediating the transport of various endogenous and xenobiotic substrates.
OATP1B3 was initially reported to be expressed exclusively in the hepatocytes where it
mediates the uptake of numerous endogenous substrates (e.g. bile acids, steroid hormone
conjugates) and several clinically relevant drugs including anticancer drugs. Later, a
number of studies reported that OATP1B3 is also frequently expressed in multiple types
of cancers and may be associated with differing clinical outcomes. However, a detailed
investigation on the expression, localization and functions of OATP1B3 expressed in
cancer has been lacking. In this thesis work, we confirmed that colon and pancreatic
cancer cells express a cancer-specific OATP1B3 variant (csOATP1B3), different from
OATP1B3 wild-type (WT) expressed in the normal liver. The csOATP1B3 utilizes an
alternative transcription initiation site and the translated product of csOATP1B3 lacks the
first 28 amino acids at the N-terminus of OATP1B3 WT. Our results show that csOATP1B3
has modest uptake transporter functions and reduced plasma membrane localization
compared to OATP1B3 WT. In our efforts to investigate the regulatory mechanism
underlying the expression of csOATP1B3, we found that hypoxia inducible factor-1α (HIF1α) may play a key role in the regulation of csOATP1B3 in colon and pancreatic cancer
cells. In a separate study, we tested whether the N-terminal sequence of OATP1B3 WT
plays an important role in the membrane trafficking. This is based on the observation that
csOATP1B3 lacking the first 28 amino acids at N-terminus of OATP1B3 WT displays a
predominantly cytoplasmic localization pattern. Using the constructs with N-terminal
truncations and point mutations, we verified that the N-terminus of OATP1B3 WT contains
important motifs in its membrane trafficking. In particular, the amino acids within a putative
β-turn-forming tetrapeptide appear to be important in regulating the membrane trafficking
of OATP1B3 WT. The findings from this thesis work provide important insights into the
functional and clinical significance of OATP1B3 in cancer and normal liver.
KEYWORDS: OATP1B3, splicing variants, colon cancer, pancreatic cancer, hypoxia,
membrane trafficking, normal liver
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Chapter 1
Rationale for Theis Work
(Each chapter of this thesis contains its own introduction and therefore this
chapter is intended to provide a brief rationale for the entire thesis.)
The roles of efflux drug transporters in cancer therapy are extensively investigated, in
particular due to their contribution to multi-drug resistance by expelling cancer drugs from
cells. In contrast, the roles of uptake transporters in cancer therapy are not as well
understood. The organic anion transporting polypeptides (OATPs, gene symbol SLCO)
represent one of the major superfamilies of solute carriers and they are expressed in
different tissues throughout the body. OATPs function as multispecific transmembrane
carriers that can transport a structurally diverse array of endogenous and xenobiotic
compounds. Substrates of OATPs include organic dyes, bile acids, prostaglandins, cyclic
nucleotides, steroid hormone conjugates, thyroid hormones, drugs, and environmental
toxins. OATPs are known to transport their substrates in a sodium-independent manner.
Common structural features of the OATP superfamily include twelve transmembrane
domains with intracellular amino and carboxy termini as well as a large extracellular loop
between the ninth and tenth transmembrane regions [1, 2] .
Among 11 human OATP members, OATP1B3 was initially reported to be expressed
exclusively in hepatocytes where it mediates the uptake of various endogenous substrates
(e.g., conjugates of bile acids or steroid hormones) and clinically relevant drugs such as
methotrexate, imatinib, SN-38, paclitaxel [3, 4]. Subsquent investigations have also
reported that OATP1B3 is frequently expressed in multiple cancer tissues derived from
the gastrointestinal tract, lungs, breast, pancreas, prostate, and testis, while no expression
was detected in nonmalignant tissues of these organs [3, 5-7]. Although some
investigations suggested a potential association between OATP1B3 expression and
1

differing clinical outcomes [8], a molecular and functional understanding of OATP1B3 in
cancer was incomplete.
In majority of the previous reports, it was assumed that OATP1B3 detected in cancer is
identical to that in the normal hepatocytes. These findings were based on the results from
RT-PCR analyses amplifying different regions in the OATP1B3 transcript and
immunodetection methods using antibodies against the C-terminal region of OATP1B3
protein [3, 5-7, 9]. In our previous report, we had noted that the immunohistochemical
staining for OATP1B3 frequently showed a cytoplasmic pattern in clinical colon cancer
tissues, in contrast to the membranous staining in normal hepatocytes [6]. This led us to
hypothesize that cancer cells may express alternative form(s) of OATP1B3
transcript/protein, different from wild-type (WT) OATP1B3 expressed in normal
hepatocytes.
This thesis consists of several chapters, each of which contains relevant background
information, results and discussions for the molecular and functional investigations of
OATP1B3 expressed in cancer and normal liver. Chapter 2 reviews the literature findings
on the expression and functions of different OATPs in cancer. In Chapter 3, we report the
identification of cancer-specific variant forms of OATP1B3 resulting from alternative
splicing in colon and pancreatic cancer. Our results indicated that colon and pancreatic
cancer cells express the cancer-specific variant of OATP1B3 (csOATP1B3) which has
limited transport activity and reduced plasma membrane trafficking compared to WT
OATP1B3 expressed in the normal liver. In Chapter 4, we investigated the mechanisms
regulating the expression of csOATP1B3. Based on the initial clues from a report by Winter
et al. [10] we investigated the role of hypoxia and the involvement of hypoxia inducible
factor-1a (HIF-1α) in regulating the transcription of csOATP1B3. Our results showed that
csOATP1B3, but not OATP1B3 WT is induced under ambient and chemical hypoxia. We

2

were also able to identify a functional hypoxia response element (HRE) located in the
proximal upstream region that physically interacts with HIF-1α.
Despite intense interest in understanding the transporter functions of OATP1B3 WT and
its role in drug-drug interactions, little has been known about the mechanisms regulating
the cellular trafficking of OATP1B3. In Chapter 5, we investigated whether the N-terminal
sequence of OATP1B3 WT contains important motifs responsible for its membrane
trafficking. This is based on the observation that the OATP1B3 variant lacking the Nterminal 28 amino acids was localized predominantly in cytoplasm. Our results indicated
that the truncation of N-terminal amino acids 12-23 leads to substantially reduced
expression and membrane localization of OATP1B3. In particular, the amino acids within
a putative β-turn-forming tetrapeptide appear to be important in regulating the membrane
trafficking of OATP1B3 WT.
In summary, the findings from this thesis work provide a better molecular and functional
understanding of cancer-type OATP1B3, which had been incorrectly presumed to be
identical to OATP1B3 WT expressed in the liver. This thesis work also provides important
insights into the regulation of cellular trafficking and expression of OATP1B3, potentially
applicable to other members of the OATP family.

Copyright © Nilay Thakkar 2015
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Chapter 2
Literature review: Role of Organic Anion Transporting Polypeptides (OATPs) in
Cancer Therapy
(The contents of this chapter have been submitted for publication in the AAPS Journal,
currently under revision).
2.1 Introduction
The Organic Anion Transporting Polypeptides (OATPs) represent an important
superfamily of solute carriers expressed in various tissues throughout the body. The
OATPs can mediate the bidirectional transport of a diverse array of endogenous and
xenobiotic compounds, including organic dyes, bile acids, prostaglandins, cyclic
nucleotides, steroid hormones and their conjugates, thyroid hormones, drugs and
environmental toxins. The majority of OATP substrates are large amphipathic organic
anions (molecular weights greater than 300 kDa), but OATPs can also transport cationic
and neutral compounds. OATPs are known to transport their substrates in a sodiumindependent manner. Common structural features of the OATP superfamily include twelve
transmembrane domains with intracellular amino and carboxy termini as well as a large
extracellular loop between the ninth and tenth transmembrane regions.
The OATP superfamily belongs to the SLCO gene family and is divided into six families
based on sequence similarities [11]. Currently, 11 human OATPs are known with the
OATP1 family being most well characterized. The OATP1 family includes four members,
OATP1A2, OATP1B1, OATP1B3 and OATP1C1, which display broad and overlapping
substrate specificity. The OATP2 family includes two members, OATP2A1 and OATP2B1,
both of which display relatively narrow substrate specificity compared to other OATPs.
The OATP4 family includes OATP4A1 and OATP4C1. The OATP3, OATP5 and OATP6
4

families include OATP3A1, OATP5A1 and OATP6A1, respectively. Orthologs of human
OATPs are reported in other species, but there are cases that no single ortholog is shared
between humans and animals. For example, human OATP1B1 and OATP1B3 have a
single rodent ortholog of Oatp1b2 [11].
Early investigations primarily focused on the identification and characterization of OATPs
expressed in various organs throughout the body and the roles of OATPs in determining
the disposition of substrates in vitro and in vivo. Subsequent reports revealed that the
expression of OATPs can be altered in different disease conditions including cancer,
implying that OATPs may play a role in the development and progression of cancer as
well as the disposition of anticancer drugs. In this chapter, we will summarize the recent
progress delineating the role of OATPs in cancer therapy. We will first summarize the
current understanding of the roles of OATPs on the disposition of anticancer drugs and
the impact of their genetic polymorphisms on the expression and function of OATPs, as
well as the use of animal models to study the role of OATPs in anticancer drug disposition.
In the later section, we will provide an update on the current knowledge about OATPs
expressed in cancer and their potential roles in cancer development, progression and
treatment.
2.2 Role of OATPs in the disposition of substrates implicated in cancer therapy
OATPs can mediate the transport of a wide range of endogenous and xenobiotic
substrates in various tissues. The endogenous substrates of OATPs include cyclic and
linear peptides, prostaglandins, bile acids, steroid hormone and their conjugates and
thyroid hormones. Diverse classes of drugs, including anticancer drugs are also
substrates of OATPs [11, 12]. In particular, the transporters of the OATP1 family have a
number of substrates relevant in cancer therapy (Table 2.1).
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Endogenous steroid hormones have been implicated in enhancing the survival and
proliferation of cancer cells. Estrone-3-sulfate (E3S) is a major form of circulating
estrogens and serves as an important source of estrogenic activity in postmenopausal
women, the population with a high incidence rate of hormone-dependent cancers. Due to
its hydrophilic and charged nature, E3S is not readily permeable across the plasma
membrane and it often relies on a transporter-mediated mechanism to enter the cells.
Among the eleven human OATP members, seven (OATP1A2, OATP1B1, OATP1B3,
OATP1C1, OATP2B1, OATP3A1 and OATP4A1) are shown to transport E3S [4, 13].
These OATPs may facilitate the uptake of E3S not only in the major organs such as the
liver, kidney, intestine and brain, but also in hormone-dependent cancers [13-15]. Similar
to E3S, dehydroepiandrosterone sulfate (DHEA-S) is transported by multiple OATPs
(OATP1A2, OATP1B1, OATP1B3 and OATP2B1) and may gain entry to cells via these
transporters [4]. On the other hand, testosterone appears to be transported only by
OATP1B3 [7, 16]. Many of these investigations however focused on the uptake of steroid
hormones and their conjugates into cancer cells and the subsequent impact on cancer
cell proliferation and related cellular pathways, rather than the disposition of hormonal
substrates in the whole body.
In case of anticancer drugs handled by OATPs, a number of investigations have examined
whether the expression/function of OATPs can influence the pharmacokinetic profiles of
anticancer drugs, and consequently therapeutic effects and toxicities. The most well
studied substrates include methotrexate, doxorubicin and taxanes (paclitaxel and
docetaxel). For these drugs, multiple reports indicated that these agents are handled by
OATP1A2, OATP1B1 and OATP1B3 [3, 17-19]. The results were obtained from various
models, ranging from in vitro heterologous expression systems, in vivo preclinical
knockout and humanized mouse models and clinical studies. Docetaxel is reported to be
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a substrate of human OATP1B1 and OATP1B3 and rat and mouse Oatp1b2 in vitro [20,
21]. However, the pharmacokinetic profiles of docetaxel were not substantially altered in
a cohort of patients harboring genetic variations associated with decreased OATP1B1 or
OATP1B3 activity [22]. These results might be related to the presence of other uptake
transporters with overlapping functions in the human liver. Indeed, a recent study using
humanized transgenic mice indicated that elevated plasma levels of docetaxel observed
in the knockout mice lacking Oatp1a/1b can be rescued by liver-specific expression of
human OATP1B1, OATP1B3 or OATP1A2, confirming the relevance and overlapping
nature of these OATP transporters in determining in vivo disposition of docetaxel [18].
When the involvement of OATPs in the handling of taxanes is considered, there was also
a report indicating that taxanes are not handled by OATP1B3 [20]. These apparent
discrepancies may be due to differences in the expression systems (Xenopus laevis
oocytes vs HEK293). Other well-studied anticancer drugs handled by OATP1B1 and
OATP1B3 are rapamycin (sirolimus) and SN-38 (7-ethyl-10-hydroxycamptothecin, an
active metabolite of irinotecan) [20, 23-26]. Additionally, OATP1B1 transports CP-724,714
(a Her2 tyrosine kinase inhibitor), cis-diammine-chloro-cholylglycinate-platinum II (a bileacid cisplatin derivative) and gimatecan (a camptothecin analog) [27-29]. Imatinib, used
for leukemia therapy, is reported to be transported by OATP1A2 and OATP1B3 [30, 31].
Further investigations will be necessary to elucidate the clinical relevance of these
transporters in influencing the in vivo disposition and therapeutic effects of these substrate
drugs.
The magnetic resonance imaging agent gadolinium-ethoxybenzyl-diethylenetriamine
pentaacetic acid (Gd-EOB-DTPA) is also shown to be transported by OATP1B1 and
OATP1B3 [32-34]. In a retrospective study involving 22 patients with hepatic cancer, high
OATP1B3 expression levels were significantly correlated with increased uptake of Gd-
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EOB-DTPA [32]. In individuals carrying certain genetic variations associated with
decreased OATP1B1 activity, the liver enhancement by the gadolinium-based imaging
agent was substantially attenuated [34]. These findings suggest that the activity of OATPs
and genetic variations may be potential confounders leading to a reduced signal intensity
in liver magnetic resonance imaging. However, a recent retrospective study took
advantage of this relationship and attempted to use the signal intensity of Gd-EOB-DTPA
as a marker for hepatic vascularity and OATP-related activity and potentially as a
prognostic factor for patients with early-staged hepatic cancer [35]. Additional
investigations will be important to evaluate the prognostic utility of these findings in
improving the classification and management of early-staged hepatic cancer.
2.3 Impact of OATP polymorphisms on the pharmacokinetics of anticancer drugs
A number of naturally occurring single nucleotide polymorphisms (SNPs) in the genes
encoding OATPs have been reported and extensively investigated for their impact on the
expression and function of the corresponding OATPs and consequently on the disposition
and efficacy of anticancer drugs. In particular, polymorphic variants of genes encoding
OATP1A2, OATP1B1 and OATP1B3 have been reported to be clinically relevant.
Comprehensive reviews on this topic are already available elsewhere [4]. Thus, only a
brief summary and update involving the disposition of anticancer drugs is provided below.
For OATP1A2, the initial investigation was carried out using Xenopus laevis oocytes
expressing genetic variants of OATP1A2 and methotrexate [17]. Four out of the twelve
OATP1A2 variants examined displayed altered transport of E3S and methotrexate; the
p.I13T (rs10841795) variant displayed enhanced transport activity, the p.R168C
(rs11568564) and p.E172D (rs11568563) variants demonstrated decreased transport
activity and the p.N278DEL (rs11568555) variant produced a nonfunctional protein.
However, the impact of these OATP1A2 variants on the pharmacokinetics of methotrexate
8

in patients remains to be determined. More recently, a similar line of investigation was
carried out with imatinib and genetic variations present in the coding and promoter regions
of the gene encoding OATP1A2 [31]. The authors were able to identify polymorphic
variations in the promoter region of OATP1A2 (−1105G>A (rs4148977) in linkage
disequilibrium with −1032G>A (rs4148978), and −361G>A (rs3764043)) which correlated
with the clearance of imatinib in patients with chronic myeloid leukemia [31]. Further
clinical studies are required to confirm these findings in a larger group of patients and to
verify whether the identified OATP1A2 variations correlate with therapeutic effects or
toxicities of imatinib.
For OATP1B1, there are several commonly occurring SNPs and in particular, the
OATP1B1*15 (harboring variations causing two amino acid substitutions, p.N130D
(rs2306283) and p.V174A (rs4149056)) variant has been most extensively investigated.
Compared to the wild-type OATP1B1 (OATP1B1*1a), the OATP1B1*15 displayed
reduced uptake of SN-38 (an active metabolite of irinotecan), when tested in in vitro cell
line models stably expressing OATP1B1 variant proteins [24]. The clinical relevance of
these findings was subsequently validated by comparing the pharmacokinetics and toxicity
profiles in patients receiving irinotecan therapy [36, 37]. Patients with the OATP1B1*15
genotype showed increased systemic exposure and toxicities of SN-38 compared to those
with the wild-type OATP1B1 [36, 37]. Similar findings have been reported with patients
treated with methotrexate. In particular, recent reports validating the relevance of the
OATP1B1*15 genotype in determining the pharmacokinetics and toxicities of
methotrexate were from genome-wide association studies or studies involving a large
number of patients and cohorts from different institutions [38-40]. Continued investigations
examining the prospective utility of the OATP1B1 genotypes in improving therapeutic
effects and safety profiles of these anticancer drugs are warranted.
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As a closely related member to OATP1B1, OATP1B3 displays substantial overlapping
substrate specificity, yet harbors fewer genetic variations. Initially, the functional impact of
three nonsynonymous SNPs of OATP1B3 (p.S112A (rs4149117), p.M233I (rs7311358)
and p.G522C (rs72559743)) were examined using in vitro models [41]. However, none of
these three SNPs were found to have a significant impact on the clearance and other
pharmacokinetic parameters of paclitaxel in cancer patients [42]. For docetaxel, a potential
association between OATP1B3 genotypes and toxicity (leukopenia/neutropenia) has been
recently reported in patients [43, 44]. Additional investigations will be required to validate
the clinical relevance of these findings.
2.4 Animal models to investigate the role of OATPs in the disposition of anticancer
drugs
Given the increasingly recognized roles that OATPs play in determining the disposition of
many drugs, it has become important to assess the potential of OATPs and their genetic
variations as a source for variable drug disposition and response in vivo. In recent years
a number of transgenic mouse models have been reported including the knockout mouse
models lacking the orthologs of human OATP1A and OATP1B subfamily members and
the humanized mouse models where human OATPs are introduced after deleting the
genes for mouse orthologs.
In rodents, there is only one member of the Oatp1b subfamily and it is considered to be
the closest ortholog for both human OATP1B1 and OATP1B3. The knockout mouse
models lacking Oatp1b2 have been developed by three independent groups and have
served as useful tools to delineate and extrapolate the in vivo relevance of both human
OATP1B1 and OATP1B3 to the disposition of environmental toxins (e.g. phalloidin,
microcystin-LR), statin drugs (e.g. cerivastatin, lovastatin, pravastatin, simvastatin) and
antibiotics (e.g. rifampicin, rifamycin SV) [45-47]. Given the large overlap in tissue
10

distribution and substrate specificity within the OATP1 family, another transgenic mouse
model deficient for all five established Slco1a and Slco1b genes (Slco1a/1b-/- mice ) has
been developed [48]. These mice lacking Oatp1a1, Oatp1a4, Oatp1a5, Oatp1a6 and
Oatp1b2 displayed drastically reduced hepatic uptake of methotrexate, fexofenadine and
paclitaxel and subsequently increased systemic exposure for all of these drugs [48, 49].
In addition, humanized transgenic mouse models expressing OATP1A2, OATP1B1 and
OATP1B3, in the absence of the background expression of the mouse orthologs, have
been developed and used to account for possible species-dependent differences between
the mouse and human OATP orthologs. For example, a humanized OATP1B1 mouse
model with liver-specific expression of OATP1B1 was generated and the disposition of
methotrexate was investigated. The plasma concentrations of intravenously administered
methotrexate in the humanized OATP1B1 transgenic mice were substantially lower than
in the control animals [50]. In addition, the humanized OATP1B1 transgenic mice
displayed a greater amount of methotrexate in the liver as well as a higher liver to plasma
ratio of methotrexate than the control animals [50]. Similarly, transgenic humanized
OATP1A/1B mouse models were generated with liver-specific expression of OATP1B1,
OATP1B3 and OATP1A2 in an Oatp1a/1b knockout background. This model was utilized
to show that paclitaxel, methotrexate, SN-38, docetaxel and doxorubcin are transported
by OATP1A/1B in vivo [18, 19, 51, 52].
These findings have provided further insights regarding the contribution of OATP1A/1B
transporters to the disposition, response and toxicity of anticancer drugs. Importantly,
those investigations have provided the impetus for additional studies to elucidate the role
of other OATPs and commonly observed polymorphisms in the pharmacokinetics and
pharmacodynamics of anticancer drugs. Together, these tools will continue to provide a
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useful guide to inform anticancer drug development and optimization of anticancer drug
therapy.
2.5 OATPs expressed in cancer
There is a substantial body of evidence indicating that the expression of OATPs can be
altered in various types of cancers. In this section we will summarize the current literature
about different OATPs expressed in cancer tissues, their proposed functions and cancerspecific mechanisms of regulation.
2.5.1 OATP1A2 (Gene symbol, SLCO1A2)
OATP1A2 expression has been confirmed in several normal tissues and cell types
including the blood-brain barrier, enterocytes, cholangiocytes and kidneys [53, 54].
OATP1A2 can mediate the transport of endogenous hormonal substrates (e.g. E3S,
DHEA-S) and several cancer drugs (e.g. imatinib, paclitaxel, doxorubicin, docetaxel)
(Table 2.1). Thus, a number of studies have examined the expression and functional
impact of OATP1A2 in cancer. OATP1A2 expression was first reported in breast cancer
and subsequently in additional types of cancer including colon, prostate and bone (Table
2.2) [55-59]. To date, the potential functional significance of OATP1A2 has been reported
in breast cancer, but not in other types of cancer.
The expression of OATP1A2 mRNA and protein in breast cancer was first reported by Miki
et al. [55]. The results from RT-PCR analyses indicated that OATP1A2 is expressed in
human breast cancer tissues, but not in noncancerous breast, adipose tissues or stromal
cells [55]. These findings are consistent with the reports showing that OATP1A2 mRNA
was barely detectable in non-malignant mammary epithelial cells (below the level of
quantification) [60]. Interestingly, Miki et al. also reported a significant correlation between
the expression of OATP1A2 and the nuclear receptor PXR (pregnane X receptor)
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providing possible insights into the regulation of OATP1A2 expression [55]. These findings
were further validated in breast cancer cell line models [56] where treatment of T47-D cells
with rifampicin (a well-known PXR activator) increased the expression of OATP1A2 and
cellular uptake of E3S and promoted breast cancer cell proliferation in vitro. In line with
these findings, a more recent study using mouse xenograft models reported that
OATP1A2 may play a role in regulating in vivo tissue distribution of E3S and the growth
of hormone-dependent breast cancer [14]. In the clinical setting, the expression of
OATP1A2 combined with another transporter OCT6 in patients with triple negative breast
cancer (which displays no detectable expression for estrogen receptor, progesterone
receptor and Her2/neu and has very poor prognosis) was predictive of response to
anthracycline/taxane-based neoadjuvant chemotherapy [61]. Further investigations will be
required to evaluate the clinical relevance of these findings in patients with hormonedependent or triple negative breast cancers.
Although detailed functional investigations have not been reported, the expression of
OATP1A2 has been observed in other cancers. Arakawa et al. reported that OATP1A2 is
expressed in human prostate cancer cell lines (LNCaP and 22Rv1) and facilitates the
uptake of DHEA-S and enhances cancer cell growth under androgen-depleted conditions
[58]. The levels of OATP1A2 mRNA were reported to be elevated in human osteosarcoma
cell lines (HOS and MG-63) and human kidney cancer cells metastasized to bone tissue
[59]. On the other hand, colon polyps and colon cancer tissues were reported to have
reduced OATP1A2 mRNA levels compared to healthy colon tissue [57].
As noted above, the nuclear receptor PXR may play a role in regulating OATP1A2
expression in cancer [56]. A PXR response element present in the human OATP1A2
promoter was confirmed to have physical interactions with PXR and to play a role in the
transactivation of OATP1A2 in breast cancer cells [56]. If OATP1A2 is eventually identified
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to have an important role in cancer development, progression or therapy, its regulation
through PXR may be a key relationship to investigate.
2.5.2 OATP1B1 (Gene symbol, SLCO1B1)
OATP1B1 is abundantly expressed in the normal liver and was initially considered to be
liver-specific [62, 63]. OATP1B1 mediates the uptake of several endogenous substrates
including hormones (E3S and DHEA-S) and anticancer drugs (rapamycin, SN-38,
gimatecan, flavopiridol, docetaxel) (Table 2.1) (reviewed in [4] and [64]). Several
investigations have been carried out to assess the expression levels and functions of
OATP1B1 in cancer. To date, OATP1B1 is reported to be expressed in colon cancer,
ovarian cancer and variably expressed in hepatocellular carcinoma (HCC).

A number of reports indicate that the expression of OATP1B1 is decreased in HCC
compared to non-malignant liver. Since the first report on the decreased OATP1B1 protein
levels in HCC cell lines [65], many subsequent investigations have reported similar
findings using HCC tissue samples and cell lines [66-69]. However, there is also a report
noting no significant reduction of OATP1B1 in HCC tissues compared to non-malignant
liver tissues [70].
In contrast to the variable expression of OATP1B1 in HCC, OATP1B1 expression was
reported to be elevated in cancers derived from nonhepatic tissues which normally do not
express OATP1B1. For instance, OATP1B1 expression has been reported in colon polyps
and colon cancer tissue [57] as well as ovarian cancer tissue samples and cell lines (SKOV-3) [9]. In regards to its transport functions in cancer, OATP1B1 is implicated to play a
role in paclitaxel uptake in ovarian cancer cells [9]. Overall, further investigations will be
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necessary to examine the clinical significance of altered expression of OATP1B1 in
cancers.
2.5.3 OATP1B3 (Gene symbol, SLCO1B3)
When OATP1B3 was cloned for the first time, it was found to be abundantly expressed in
the normal liver, but not in any other non-malignant tissues [3]. This initial report also noted
that OATP1B3 is expressed in multiple types of cancer. These findings have been
confirmed by a number of subsequent investigations and OATP1B3 is arguably the most
extensively investigated OATP member with regard to cancer-related alterations in
expression. Recently there has been substantial progress in our understanding of cancerspecific expression of OATP1B3 including the identification of cancer-specific variants.

OATP1B3 mediates the transport of several endogenous substrates including hormones
(E3S, DHEA-S, testosterone), cancer drugs (methotrexate, imatinib, paclitaxel, SN-38,
rapamycin, docetaxel, doxorubicin), microcystins and MRI contrast agents (gadoliniumethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)) [32, 71]. Similar to
the decreased expression of the closely related member OATP1B1 in HCC, OATP1B3
expression was shown to be decreased in primary and metastatic liver cancers [68, 70,
72]. It has been suggested that the decreased expression of OATP1B3 and OATP1B1 in
hepatic cancer tissues may be related to poor differentiation status in the malignant
tissues. On the other hand, OATP1B3 is frequently expressed in several cancerous
tissues derived from the gastrointestinal tract, pancreas, lung, breast, prostate, and testes,
all of which do not express any detectable level of OATP1B3 in noncancerous settings.
This frequent expression of OATP1B3 across multiple cancer types prompted many
investigators to probe the functional role of OATP1B3 in cancer.
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The expression of OATP1B3 in multiple types of cancer was first reported by Abe et al.
[3]. Specifically, northern blot analyses showed the expression of OATP1B3 in various
established cancer cell lines (derived from the colon, stomach, pancreas, gall-bladder and
lung) and clinical samples (from gastric, colon and pancreatic cancer) [3]. This finding was
subsequently

corroborated

by

multiple

studies

which

utilized

RT-PCR

and

immunohistochemical detection methods (Table 2.2). In human breast cancer, OATP1B3
was detected in approximately 50% of the clinical tissue samples examined by
immunohistochemistry and OATP1B3 immunoreactivity was associated with a decreased
risk of recurrence and improved prognosis [5]. The authors speculated that OATP1B3
overexpression may be associated with hormone-dependent growth mechanisms
considering that OATP1B3 transports E3S. In line with these findings, subsequent studies
have also suggested that OATP1B3 contributes to the growth of estrogen-dependent
breast cancer [13, 15]. OATP1B3 is also reported to be expressed in prostate and
colorectal cancers [7, 8, 16]. In reference to colorectal cancer, OATP1B3 is found to be
expressed in the majority (56%) of clinical tissue specimens examined, and possibly
associated with improved clinical outcomes [8]. During these investigations, it was also
noted that the immunohistochemical staining for OATP1B3 showed predominantly a
cytoplasmic pattern, clearly different from the membranous pattern in normal hepatocytes
[6, 8].
Our laboratory has probed possible reasons for different localization patterns of
OATP1B3 expressed in cancer cells vs normal hepatocytes. Through those efforts, we
recently reported the presence of a cancer-specific OATP1B3 variant (csOATP1B3 or
OATP1B3 V1) which utilizes an alternative transcription initiation site from wild-type (WT)
OATP1B3 expressed in normal liver [73]. The protein translated from the longest open
reading frame (ORF) lacks 28 amino acids at the N-terminus of OATP1B3 WT. Our
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findings showed that in comparison to OATP1B3 WT, csOATP1B3 has defective plasma
membrane trafficking, resulting in reduced transport activity of cholecystokinin-8 (a
prototype OATP1B3 substrate) [73]. Similarly Nagai et al. reported that lung, colon and
pancreatic cancer tissues and cell lines express an alternative OATP1B3 transcript [74].
However, this study proposed the four potential ORFs resulting in much shorter amino
acid sequences than the ORF reported by our laboratory and another subsequent report
[73, 75]. Currently, csOATP1B3 is found to be the major isoform expressed only in cancer
cells, but not in normal tissues. Further studies are required to delineate the biological
significance of csOATP1B3 in cancer, specifically whether csOATP1B3 confers any
survival advantage or chemotherapy resistance to cancer cells.
With regard to the regulatory mechanisms for OATP1B3 expression, several
investigations implicated the involvement of the liver-enriched transcription factor,
hepatocyte nuclear factor 3β, (HNF3β) as well as epigenetic and hypoxia mediated
mechanisms [70, 75-77]. The contribution of these reported mechanisms may vary
depending on the tissue types and disease states. In an earlier report, Vavricka et al
showed that HNF3β is responsible for the transcriptional repression of OATP1B3
expression in HCC [70]. A later study showed that epigenetic mechanisms by DNA
methylation-dependent gene silencing are involved in the regulation of OATP1B3 in
different cancer cell lines [76]. A more recent study showing that DNA methylationdependent gene silencing involving the Methyl-DNA Binding protein 2 (MBD2) regulates
the expression of csOATP1B3 confirmed the previous methylation-dependent gene
silencing findings [75]. Our laboratory showed that csOATP1B3, but not OATP1B3 WT is
transcriptionally activated by hypoxia. A functional hypoxia response element (HRE) within
the promoter regions of csOATP1B3 was shown to physically interact with hypoxia
inducible factor-1α (HIF-1α) in colon and pancreatic cancer cells [77]. We postulated that
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hypoxia-induced regulation of csOATP1B3 may be operating in line with epigenetic
regulation. This hypothesis is based on the observation that the HRE site proposed in our
recent study [77] is located in close proximity to the potential methylation site [75]. Thus,
we examined the effect of in vitro methylation on the transactivation of a reporter construct
of the csOATP1B3 promoter containing the proposed HRE and methylation sites. Our
results showed no substantial changes by in vitro methylation, suggesting that hypoxia
and epigenetic mechanisms likely work independently in regulating the csOATP1B3
(unpublished data).
2.5.4 OATP1C1 (Gene symbol, SLCO1C1)
OATP1C1 was identified as a high affinity transporter for thyroid hormones in brain, Leydig
cells of the testis [78] and ciliary bodies [79]. Thus far, no cancer drugs have been
identified to be substrates of OATP1C1. A study by Liedauer et al. showed that OATP1C1
mRNA expression was detected in several human osteosarcomas, samples of metastases
from kidney tumors and the highest expression was observed in aneurysmal bone cysts
[59]. This is the only study to report the expression of OATP1C1 in cancer and the
functional role of OATP1C1 in bone cancers is currently unknown.
2.5.5 OATP2A1 (Gene symbol, SLCO2A1)
OATP2A1 was initially cloned and identified as a prostaglandin transporter [80]. Currently,
no cancer drugs have been reported to be substrates of OATP2A1. In non-cancerous
tissues, OATP2A1 is expressed ubiquitously. Altered expression of OATP2A1 is reported
in various types of cancers (Table 2.2). OATP2A1 expression is reported to be increased
in breast cancer, HCC, cholangiocarcinoma and liver metastases from colon cancer [16,
81]. On the other hand, reduced OATP2A1 levels are reported in other types of cancer
from colon, stomach, ovary, lung, and kidneys [82]. Interestingly, the reduced expression
of OATP2A1 was linked with increased extracellular levels of the proinflammatory
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prostaglandin E2 (PGE2) in colorectal cancer [82]. Higher extracellular levels of PGE2
may activate various signaling cascades in colorectal cancer by interacting with G proteincoupled receptors on the surface. Further investigations are required to better understand
the impact of altered OATP2A1 expression in cancer.
2.5.6 OATP2B1 (Gene symbol, SLCO2B1)
OATP2B1 is a ubiquitously expressed uptake transporter that was initially cloned by Tamai
et al. [83] (Table 2.2). OATP2B1 transports various substrates including steroid hormone
conjugates, thyroid hormones, prostaglandins and other drugs. Although no cancer drugs
are currently known to be substrates of OATP2B1, its altered expression is reported in
different cancers (Table 2.2). In breast cancer, increased OATP2B1 expression was
reported in clinical samples as well as cell lines and was correlated with high tumor grades,
but not with an altered clinical outcomes [84]. OATP2B1 expression was also shown to be
higher in bone cysts compared to osteosarcoma tissues [59]. Alternatively, Pressler et al.
showed that OATP2B1 mRNA expression was lower in liver and pancreatic cancers
compared to non-malignant tissues [85]. However, these findings have not been validated
at the protein level. Currently, the role of OATP2B1 in cancer cells is not well understood
and needs further investigation.
2.5.7 OATP3A1 (Gene symbol, SLCO3A1)
In non-malignant tissues, OATP3A1 is expressed ubiquitously where it transports various
hormones, prostaglandins and drugs [4]. Altered expression of OATP3A1 is reported in
various types of cancers (Table 2.2). Increased expression of OATP3A1 transcripts have
been reported in multiple cancer cell lines [4, 83]. Higher OATP3A1 mRNA was detected
in aneurysmal bone cysts as compared to osteosarcomas [59]. In breast cancer,
OATP3A1 is localized both on the plasma membrane and in the cytoplasm [86]. Wleck et
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al. showed that OATP3A1 levels were increased in primary and metastatic liver cancer
[87]. Further studies are required to investigate the role of OATP3A1 expressed in cancer.
2.5.8 OATP4A1 (Gene symbol, SLCO4A1)
OATP4A1 is expressed ubiquitously and plays a role in the transport of several
endogenous (hormones, prostaglandins and bile acids) and drug substrates (reviewed in
[4]). Similar to OATP3A1, OATP4A1 is also overexpressed in multiple cancer cell lines,
aneurysmal bone cysts, liver cancers and breast cancers [59, 81, 83, 87]. In colorectal
neoplasia specimens, OATP4A1 mRNA levels were reported to be elevated [88].
Additionally, the authors suggested that increased expression of PGE2 transporting
OATP2B1 and OATP4A1 may lead to decreased sensitivity to cyclic nucleotides in
colorectal neoplasia. However further validation is required to better delineate the role of
OATP4A1 in these conditions.
2.5.9 OATP4C1 (Gene symbol, SLCO4C1)
OATP4C1 expression in non-cancerous tissues is mainly limited to the kidney where it
mediates the uptake of thyroid hormone, cAMP, cardiac glycosides, and methotrexate
[89]. In breast cancer tissues and cell lines, Wleck et al. showed that elevated OATP4C1
mRNA levels were present [81]. However, little is known regarding the expression and
role of OATP4C1 in other cancers.
2.5.10 OATP5A1 (Gene symbol, SLCO5A1)
OATP5A1 is reported to be expressed in the epithelial cells lining the mammary ducts [86].
To date, the tissue distribution and substrates of OATP5A1 are poorly understood.
Different studies report the expression of OATP5A1 in cancers (Table 2.2).
Immunohistochemical analyses confirmed that OATP5A1 is expressed on the membrane
and in the cytoplasm of breast cancer cells [86]. OATP5A1 at both the mRNA and protein

20

levels was found to be upregulated in liver cancer [87] and small cell lung cancer (SCLC)
[90]. As a potential marker of chemotherapy resistance, HEK-293 cells transfected with
OATP5A1 showed resistance to satraplatin treatment [90]. Further studies may be
warranted to elucidate the impact of OATP5A1 on tumor resistance and better understand
the role OATP5A1 in cancer.
2.5.11 OATP6A1 (Gene symbol, SLCO6A1)
OATP6A1 was initially identified as a gonad-specific transporter expressed predominantly
in the testes [91, 92]. Its expression is also reported in cancer tissues (lung esophageal,
and bladder) and lung cancer cell lines [92]. However, little is currently known regarding
the role of OATP6A1 expression in cancer.
2.6 Conclusions and Outlook
OATPs are expressed in multiple tissues and organs and mediate the transport of a wide
range of substrates in a sodium-independent manner. It is increasingly recognized that
OATPs play an important role in the disposition of substrates implicated in cancer therapy.
In particular, the variable expression/activity of OATP1 family members and their genetic
variations have been extensively investigated as a possible source for altered
pharmacokinetics and pharmacodynamics of anticancer drugs. There is a long list of
anticancer drugs recognized as OATP substrates, but further research is required to
elucidate the in vivo relevance of these interactions. The increasing availability of
transgenic mouse models is moving the field forward, yet further clinical validation in terms
of disposition, response and toxicity to anticancer drugs will be crucial.
It is now well recognized that certain OATPs are differentially regulated in normal and
cancer tissues. Certain OATPs differentially regulated in cancer may have pathogenic
roles during cancer development and progression and potentially serve as therapeutic
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targets. Further studies are necessary to obtain more comprehensive profiles of OATPs
differentially regulated in cancer cells, along with a better understanding of molecular
mechanisms underlying altered expression of OATPs in cancer. So far, many of the
reports focused on the altered expression of certain OATPs and it will be important to
clarify the functional implications of OATPs during the development and progression of
cancers. Recently there has been progress in our understanding of the OATP1 family in
terms of their expression, regulation and potential functions in cancer cells. With the
wealth of provocative data generated, further studies are warranted to investigate the
potential roles of other OATP family members expressed in cancer.
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Table 2.1 Selected endogenous substrates, anticancer drugs and imaging agents transported by OATPs
OATPs
OATP1A2

OATP1B1
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OATP1B3

Substrates
Endogenous hormones and conjugates
Estrone-3-sulfate, DHEA-S
Anticancer drugs
Imatinib, Methotrexate, Paclitaxel, Doxorubicin, Docetaxel
Endogenous hormones and conjugates
Estrone-3-sulfate, DHEA-S
Anticancer drugs
Methotrexate, Paclitaxel, Rapamycin, Flavopiridol, SN-38,
Gimatecan, Doxorubicin, Docetaxel, CP-724,714 , Cisdiammine-chloro-cholylglycinate-platinum(II)
Imaging agents
Gd-EOB-DTPA
Endogenous hormones and conjugates
Estrone-3-sulfate, DHEA-S, Testosterone
Anticancer drugs
Rapamycin, Methotrexate, Paclitaxel, Doxorubicin, Docetaxel,
Imatinib, SN-38
Imaging agents
Gd-EOB-DTPA

Reference(s)

[93, 94]
[17-19, 30, 52]
[83, 95]
[3, 19, 96], 23, 24, 97]
[18, 27, 29, 52]
[28]
[33]
[7, 95, 97]
[3, 19, 21, 23, 52]
[18, 20, 21, 30]
[32]

Table 2.2 Expression of OATPs in non-malignant and malignant tissues

OATPs
OATP1A2

OATP1B1

Non-malignant
tissues

Alterations
 in breast cancer [55, 56]
 in colon polyps and colon
cancer [57]
 in prostate cancer cells [58]
 in bone cancer [59]

Liver [62, 63]

 in liver cancer [65-68, 85]
 in colon polyps and colon
cancer [57]
 in ovarian cancer [9]

RT-PCR, IF, IB
RT-PCR

 in liver cancer [70]
 in colon cancer [6, 73, 74]

qRT-PCR, IB
RT-PCR, qRT-PCR,
IB, IHC
RT-PCR, qRT-PCR,
IB, IHC
RT-PCR, qRT-PCR,
IF
qRT-PCR, IF

Liver [3, 99]

 in pancreatic cancer [73, 74,
100]
 in lung cancer [67]
 in prostate cancer [7, 16, 85,
101]
 in breast cancer [5]
 in testicular cancer [85]
 in ovarian cancer [9]
OATP1C1

Detection method

Blood-brain barrier [53]
Enterocytes [54]
Cholangiocytes [54]
Kidney [98]
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OATP1B3

Malignant tissues and cells

Brain [78]
Testes [78]
Ciliary body [79]

 in bone cancers [59]

RT-PCR, IF
RT-PCR
qRT-PCR
RT-PCR

RT-PCR

qRT-PCR, IHC
qRT-PCR, IF
RT-PCR
RT-PCR

OATP2A1

Ubiquitous [102]

 in breast cancer [81]
 in liver cancer [87]
 in bone metastases from kidney
cancer [59]
 in cancers of bowel, stomach,
ovary, lung and kidney [82]

qRT-PCR
qRT-PCR, IF
qRT-PCR, IB
RT-PCR

Blood-brain barrier [103]
Heart [104]
Enterocytes [105]
Liver [106]
Placenta [107]

 in bone cancer [59]
 in breast cancers [81, 84]
 in liver and pancreatic cancers
[85]

OATP3A1

Ubiquitous [108]

 in bone cysts [59]
RT-PCR
 in breast cancer tissues and cell qRT-PCR, IF, IHC
lines [86]
 in primary and metastatic liver
qRT-PCR, IF
cancer [87]
 in cancer cell lines of multiple
RT-PCR
tissues [83]

OATP4A1

Ubiquitous [83]

 in bone cysts [59]
detected in breast cancer [81]
 in primary and metastatic liver
cancer [87]
detected in cancer cell lines of
multiple tissues [83]
 in colon cancer [88]
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OATP2B1

OATP4C1

Kidney [89]

detected in breast cancer cell lines
[81]

RT-PCR
qRT-PCR, IF, IB
qRT-PCR

RT-PCR
RT-PCR
qRT-PCR, IF
RT-PCR
qRT-PCR
RT-PCR

OATP5A1

OATP6A1

Lactiferous ducts of
breast [86]

Testes [91]

 in breast cancer [86]
 in primary and metastatic liver
cancer [87]
 in small cell lung cancer [90]
detected in lung, bladder and
esophageal cancer [92]

qRT-PCR, IF, IHC
qRT-PCR, IF
qRT-PCR, IF
RT-PCR

, increased; , decreased; detection methods represented as reverse transcriptase-polymerase reaction (RT-PCR),
quantitative RT-PCR (qRT-PCR), immunofluorescence (IF), immunoblotting (IB), immunohistochemistry (IHC)
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Chapter 3
A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic
anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm
of colon and pancreatic cancer cells
(The work in this chapter has been published in Molecular Pharmaceutics (2013) [73])
3.1 Introduction
Organic anion transporting polypeptide 1B3 (OATP1B3) belongs to the OATP superfamily
that mediates transmembrane transport of endogenous and xenobiotic compounds in
various organs [2]. OATP1B3 was initially reported to be expressed exclusively in
hepatocytes, mediating the uptake of various endogenous substrates (e.g. conjugates of
bile acids or steroid hormones) and clinically relevant drugs such as methotrexate and
paclitaxel [109]. Several investigations including one from our own laboratory have shown
that OATP1B3 is also expressed in cancer tissues derived from the gastrointestinal tract,
breast, lung, pancreas and prostate, while expression was not detected in nonmalignant
tissues of these organs [3] [5-7, 67, 110]. Although some reports suggested a possible
association between OATP1B3 expression and differing clinical outcomes, a molecular
and functional understanding of OATP1B3 in cancer has been incompletely investigated
[5, 8].
In the majority of previous reports, it was assumed that OATP1B3 detected in cancer is
identical to that in normal hepatocytes [3, 5-7, 9, 67]. These findings were based on results
from RT-PCR analyses amplifying various regions in the OATP1B3 transcript and
immunodetection methods using antibodies against the C-terminal region. In our previous
study, we however noted that the immunohistochemical staining for OATP1B3 frequently
showed a cytoplasmic pattern in clinical colon cancer tissues, in contrast to the
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membranous staining in normal hepatocytes [6, 8]. This led us to hypothesize that cancer
cells may express alternative form(s) of OATP1B3 transcript/protein, different from wildtype (WT) OATP1B3 expressed in normal hepatocytes. In our current study, we have
identified multiple variant forms of OATP1B3 resulting from alternative splicing in colon
and pancreatic cancer. In a similar line of work, Nagai et al. recently reported that colon,
lung and pancreatic cancer tissues and cell lines express an alternative OATP1B3
transcript and its sequence is identical to the most prevalent variant form, OATP1B3 V1
identified from our current study [74]. Using the sequence information for this cancerspecific OATP1B3 isoform (Ct-OATP1B3 or OATP1B3 V1), Nagai et al. proposed the four
putative open reading frame (ORF) sequences and reported the detection of GFP
expression following transfection of the expression plasmids containing the proposed ORF
sequences fused with GFP [74]. However, further investigation is necessary to determine
whether any of the putative ORF sequences proposed by Nagai et al. is indeed translated
into proteins in clinical cancer tissues or established cancer cell lines [74].
In this chapter, we report our findings on the presence of multiple OATP1B3 mRNA
isoforms and further validation of the OATP1B3 V1 protein expression in clinical colon and
pancreatic cancer tissues and established cell lines. Our immunohistochemical analyses
support that colon and pancreatic cancer tissues express OATP1B3 V1 protein lacking 28
amino acids at the N-terminus. Compared to OATP1B3 WT, OATP1B3 V1 was found to
undergo a differing extent of post-translational modifications, proteasomal degradation,
and plasma membrane trafficking, and showed only limited transport activity toward
cholecystokin-8 (CCK-8, a prototype OATP1B3 substrate).
3.2 MATERIALS AND METHODS
3.2.1 Chemicals and Reagents
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Peptide: N-glycosidase F (PNGase F) was purchased from New England Biolabs Inc.
Sodium butyrate, ammonium sulfate, and rifampin were purchased from Sigma-Aldrich.
Epoxomicin was synthesized and kindly provided by Dr. Kyung Bo Kim (University of
Kentucky). [3H]-Cholecystokinin-8 ([3H]-CCK-8, 104.2 Ci/mmol, > 90% purity) was
purchased from Perkin Elmer. Immunohistochemistry reagents were purchased from
Biogenex.
3.2.2 5′-RACE (Rapid Amplification of cDNA Ends)
Total RNAs (1 g) from 5 clinical colon cancer tissues (Biochain) and 8 colon cancer cell
lines (CaCO2, HCT8, RKO, SW480, SW620, HCA7, HCT116, and DLD1) were converted
to RACE-ready cDNA using the SMARTerTM RACE cDNA amplification kit (Clontech).
Subsequently, reverse transcription-PCR (RT-PCR) was performed using the Advantage
2 PCR kit (Clontech), the universal primer provided in the SMARTerTM Race kit and
primers

designed

to

target

OATP1B3

GCCACGAAGCATATTCCCCATGAAGACA-3´)

at

or

exon
exon

5
10

(5´(5´-

CCGGCAACTGATTTGCTTTCGCAGAT-3´). Amplified products of different sizes were
cloned into pCR2.1-TOPO (Invitrogen) and analyzed by direct sequencing.
3.2.3 Quantitative and Qualitative RT-PCR
Total RNAs (1 µg) from clinical cancer tissues (n=5 for colon and n=10 for pancreas) and
multiple established cancer cell lines (n=8 for colon and n=6 pancreas) were converted to
single-stranded cDNA using the SuperScriptTM III cDNA synthesis kit (Invitrogen). For
quantitative RT-PCR analyses of OATP1B3 WT or V1, primers were designed to amplify
the regions unique to WT or V1. The following primer sequences were used; for WT, sense
5´-TCAAAGTCAAGGTGATCATT-3´

(exons

1

CCAAGAACATCTTGAATCCA-3´

(exons

2

AAAACTAGCAGATGTTCTTG-3´

(exons

2a
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and
and
and

2)
3);
3)

and
for
and

antisense
V1,

5´-

sense

5´-

antisense

5´-

ATACCTATAATATCCCATGAAGAA-3´ (exons 4 and 5); for β–actin, sense 5´GCATCCTCACCCTGAAGTAC-3´ and antisense 5´-GATAGCACAGCCTGGATAGC-3´.
Quantitative RT-PCR was performed in duplicate using iCycler with the iQ SYBR-green
Supermix (Bio-Rad). The condition of quantitative RT-PCR was as follows: annealing at
60°C with 40 cycles for OATP1B3 WT or V1; annealing at 65°C with 40 cycles for β–actin.
In order to obtain the transcript copy numbers for OATP1B3 WT, V1 or β-actin, serial
dilutions of the plasmids containing each amplicon were used as calibration samples. The
specificity of each PCR run was verified by melting curve and agarose gel analyses as
well as by confirming the mutually exclusive amplification of OATP1B3 WT or V1 using
the respective primers.
In order to examine the presence of full-length transcripts of OATP1B3 WT or V1 spanning
from the first to the last exons, qualitative RT-PCR was performed using Platinum
Supermix (Invitrogen) and the following primers; for WT (exons 1-15, expected size of
2214

bp),

sense

5´-GGATGGACTTGTTGCAGTTG-3´

and

antisense

5´-

TTAGTTGGCAGCAGCATTGT-3´; for V1 (exons 2a-15, expected size of 2077 bp), sense
5´-CAATGTATGGCCACGTTACT-3´ and antisense 5´-TTAGTTGGCAGCAGCATTGT-3´.
Each PCR cycle consisted of a denaturation step at 94°C for 30 sec, a primer-annealing
step at 55°C for 1 min, and an extension step at 72°C for 1 min. The PCR products were
visualized on 1% agarose gel.
3.2.4 Antibodies
In addition to the polyclonal OATP1B3 antibody, SKT (epitope: the C-terminal peptide
sequence SKTCNLDMQDNAAAN) validated previously,2 the polyclonal OATP1B3
antibody MFL (epitope: the N-terminal sequence of OATP1B3 V1, MFLAALSFSY) was
developed by immunizing a rabbit with the synthesized epitope sequence (Pocono Rabbit
Farm & Laboratory, Inc.). The monoclonal Myc antibody (Cell Signaling) was used in
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detecting the exogenously expressed OATP1B3 V1 or WT containing Myc tag sequence.
β-actin, Na+/K+ ATPase and calnexin (Cell Signaling) were used as gel loading controls or
a fractionation marker.
3.2.5 Immunohistochemistry
Paraffinized tissue sections of normal liver, colon and pancreatic cancer (US Biomax, Inc)
were stained to detect the expression of OATP1B3 protein. Briefly, the tissue sections
were subjected to the antigen retrieval using citrate buffer, followed by blocking with 2%
BSA. Subsequently, the sections were incubated with polyclonal OATP1B3 antibodies,
SKT or MFL, detecting the C-terminal or N-terminal sequence of OATP1B3 V1,
respectively. The tissue sections were incubated with avidin-biotin blocking reagents,
followed by incubation with biotinylated anti-rabbit IgG and streptavidin-HRP conjugates.
The positive signals were visualized using 3,3’-diaminobenzidine (DAB). The nuclei were
counterstained using hematoxylin. As a negative control, the same tissue sections were
incubated with blocking buffer lacking the primary antibody. The specificity of MFL
antibody was also validated using the antibody preincubated with 100 µg of antigenic
peptide (ThermoFisher Scientific).
3.2.6 Cloning and Plasmid Construction
OATP1B3 WT-Myc/pCMV6-Entry, the expression plasmid containing the ORF of
OATP1B3 WT and Myc tag sequence, was purchased from Origene. OATP1B3 V1Myc/pCMV6-Entry, the expression plasmid containing the ORF of OATP1B3 V1 and Myc
tag sequence was prepared by replacing the OATP1B3 WT sequence with the OATP1B3
V1-specific sequence cut from the cloned sequences of 5´-RACE products. An expression
plasmid containing the exon 2a sequence in front of the ORF of OATP1B3 V1 sequence
was also prepared for comparison purposes. All plasmids were verified by direct
sequencing.
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3.2.7 Cell Culture and Plasmid Transfection
Human cancer cell lines derived from colon cancer (CaCO2, HCT8, RKO, SW480,
SW620, HCT116 and DLD1) and pancreatic cancer (AsPC-1, BxPC-3, Panc-1,
MiaPaCa2, Capan-1 and Capan-2) were obtained from American Type Culture Collection
(ATCC) and maintained in culture conditions recommended by ATCC. HCA7 cells were
kindly provided by Dr. R. Coffey (Vanderbilt University) and maintained in DMEM
supplemented with 10% FBS (HyClone). For further investigation of OATP1B3 V1 or WT
expression and function, HCT116, HCT8 and Panc-1 cells were transiently transfected
with the expression plasmids for OATP1B3 V1-Myc or WT-Myc as well as the empty
vector, using Lipofectamine 2000 (Invitrogen) (for HCT116) or Fugene HD (Promega) (for
HCT8 and Panc-1). Protein expression analysis, immunofluorescence microscopy and
transport assays were typically carried out 48 hours after transfection.
3.2.8 Immunoblotting Analysis
Cell lysates were prepared in lysis buffer (10 mM Tris, 150 mM NaCl, 1% sodium
deoxycholate, 0.1% SDS, 1% Triton X-100, pH 7.4) containing protease inhibitors
(Roche). In order to reduce the formation of protein aggregates, cell lysates were mixed
with 4x Laemmli buffer and incubated for 30 min at room temperature. Equivalent amounts
of protein from whole cell lysates were separated by SDS-PAGE and transferred to a
PVDF membrane. The membranes were incubated overnight with the following primary
antibodies: OATP1B3 (SKT), Myc tag, β-actin, Na+/K+ ATPase, calnexin. The
immunoreactive proteins were detected using a secondary antibody conjugated with
horseradish peroxidase and an enhanced chemiluminescence substrate (Pierce).
In order to examine the extent of glycosylation of OATP1B3 V1-Myc and WT-Myc proteins,
cell lysates were prepared following transient transfection of HCT116 with the
corresponding constructs. OATP1B3 V1-Myc and WT-Myc proteins were pulled down
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from total lysates prepared as described above using the Myc antibody and Protein Gagarose beads. For preclearing, 500 μg of total lysate was incubated with Protein Gagarose beads (Roche) for 30 min at 4 °C. After centrifugation, the precleared supernatant
was collected and incubated with Myc antibody and Protein G-agarose beads overnight
at 4 °C. After centrifugation, beads were washed five times with PBS (pH 7.4). Proteins
bound to the beads were treated with PNGase F and subsequently incubated with
Laemmli buffer for 30 min at room temperature. The resulting samples were analyzed by
immunoblotting as described above.
To investigate the involvement of the proteasomal and lysosomal degradation pathways
in handling of OATP1B3 V1 or WT, HCT116 cells were incubated with epoxomicin (50 nM,
a proteasome inhibitor) or ammonium chloride (20 mM, a lysosomal inhibitor) for 6 hours
following transient transfection of OATP1B3 V1 or WT. The cell lysates were subjected to
immunoblotting as described above.
3.2.9 Transport Activity Assay Using Radiolabeled Cholecystokinin-8
In order to assess the transport activity of OATP1B3 V1, cellular uptake of CCK-8, a
prototype OATP1B3 substrate, was measured following transient transfection. First,
HCT116, HCT8 and Panc-1 cells were seeded onto a 12 well plate (2.5×105 cells per well)
24 hours before transfection. Subsequently the cells were transfected with the expression
plasmids for OATP1B3 V1 or WT as well as the empty vector. Twenty-four hours after
transfection, the cells were treated with 5 mM sodium butyrate overnight. On the day of
the experiment, cells were washed three times with pre-warmed Opti-MEM (Invitrogen) at
37 °C. The uptake was initiated by adding 0.5 ml Opti-MEM containing 3H-Cholecystokinin8 (3H-CCK-8, 0.01 µM) with or without rifampin (100 µM, an OATP1B3 inhibitor) to each
well. After a 6 min incubation (verified to be in the linear range from a separate timedependent uptake study) at 37°C, the uptake solution was removed and each well was
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washed thrice in ice-cold PBS. The cells were lysed with 0.5 N NaOH on a shaker for 30
min. The lysates were normalized in 2.5 N HCl and 250 µl of lysate was added to 3 ml of
LSC cocktail and radioactivity was measured using the TriCarb LSC counter (Perkin
Elmer). The 3H-CCK-8 uptake in each well was normalized to the protein amount
measured using the BCA protein assay (Pierce). The protein expression of OATP1B3 V1
or WT in each experiment was also verified by immunoblotting analyses.
3.2.10 Cell Fractionation Using Surface Biotinylation
In order to further investigate subcellular localization of OATP1B3 V1, fractionation using
surface biotinylation was carried out in HCT116 (expressing endogenous OATP1B3 V1)
and HCT8 cells (following transient transfection with OATP1B3 V1-Myc or OATP1B3 WTMyc). Briefly, cells were washed with ice-cold PBS-Ca2+/Mg2+ (138 mM NaCl, 2.7 mM KCl,
1mM MgCl2, 1.5 mM KH2PO4, 0.1 mM CaCl2) and then treated with a membraneimpermeable biotinylating agent (1.5 mg/ml sulfo-NHS-SS-biotin, Pierce) at 4 °C for 1 hr.
Subsequently, the cells were washed three times with ice-cold PBS-Ca2+/Mg2+ containing
100 mM glycine and incubated for 20 min at 4 °C with the same buffer to remove the
remaining labeling agent. After washing, cells were disrupted with a lysis buffer containing
protease inhibitors (Roche). Following centrifugation, streptavidin agarose beads (Pierce)
were added to cell lysates and incubated for 1 hr at 4 °C. The beads were centrifuged and
supernatant was collected as the cytoplasmic fraction. The beads were washed three
times with ice-cold lysis buffer, and biotinylated proteins were released by incubation of
the beads with Laemmli buffer for 30 min at room temperature. The biotinylated
(membrane fractions) and cytoplasmic fractions were subjected to immunoblotting.
3.2.11 Immunofluorescence Microscopy
HCT8 cells were transfected with OATP1B3 WT or V1 (myc tagged and untagged) as
described above. Twenty-four hours after transfection, cells were seeded onto 4 chamber
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culture slides (BD Biosciences) and stabilized in growth media containing 5 mM sodium
butyrate. Forty-eight hours after transfection, the cells were fixed with 4%
paraformaldehyde in ice-cold PBS for 30 min. The cells were then permeabilized with PBS
containing 0.3% Triton X-100 for 20 min at room temperature and blocked using PBS
containing 2% BSA for 1 hour at room temperature. The cells were incubated in the Myc
tag antibody followed by incubation with a secondary antibody conjugated to Alexa fluor
488 or Alexa fluor 546 dye (Invitrogen). Nuclear DNA was stained with DAPI (Vector
Laboratories Inc.). The immunofluorescence was detected using a Nikon (Eclipse Ti-U)
fluorescence microscope.
3.2.12 Statistical Analysis
The results are expressed as mean ± SD. The statistical significance between groups in
the transport studies was determined using one-way ANOVA followed by the NewmanKuels test. P values of ≤ 0.05 were considered to be statistically significant. The
calculations were done using GraphPad Prism 5.04.
3.3 RESULTS
3.3.1 Identification of OATP1B3 V1 as the Predominant Variant Expressed in Colon and
Pancreatic Cancer
To examine whether cancer cells express OATP1B3 variants differing from the WT
expressed in the normal liver, we performed 5′-RACE and RT-PCR using RNAs isolated
from clinical colon cancer tissues and established colon cancer cell lines. Subsequent
cloning and sequencing analyses revealed the identity of novel variants of OATP1B3.
Among 16 OATP1B3 variants identified so far, OATP1B3 V1 was found to be most
prevalent, detected in 10 out of 13 samples initially tested. The OATP1B3 V1 transcript is
almost identical to the WT sequence, with exception to an alternatively spliced exonic
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sequence, termed as exon 2a, in place of exons 1 and 2 in the WT transcript (Fig. 3.1A).
The intron-exon organization of OATP1B3 WT and V1 is summarized in Table 3.1. All
intron/exon boundaries are in accordance with the canonical splicing consensus motifs.

To determine the presence of the full-length transcript of OATP1B3 V1 or WT in clinical
colon and pancreatic cancer tissues, we performed qualitative RT-PCR with primers
amplifying the regions encompassing the entire ORFs for OATP1B3 V1 or WT (Fig. 3.1B).
RT-PCR results indicated that majority of the tested clinical colon and pancreatic cancer
samples express OATP1B3 V1, but not OATP1B3 WT. On the other hand, neither
OATP1B3 V1 nor WT was detected in nonmalignant colon and pancreatic tissue samples,
suggesting that OATP1B3 V1 is expressed in a cancer-specific manner. As expected,
OATP1B3 WT was detected readily in normal liver control whereas V1 was not. Next, we
further quantified the expression levels of OATP1B3 V1 and WT in colon and pancreatic
cancer cell lines by quantitative RT-PCR (Fig. 3.1C). In line with the results obtained using
clinical tissue samples (Fig. 3.1B), OATP1B3 V1 was detected in the majority of these cell
lines at varying levels. In contrast, OATP1B3 WT was not detectable in any of the tested
samples except the normal liver. Taken together, our data showed that colon and
pancreatic cancer cells express OATP1B3 V1 containing the initial exonic sequence
different from OATP1B3 WT.
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Table 3.1. Intron-exon organization of OATP1B3 gene
Exonic boundaries of OATP1B3 WT and OATP1B3 V1 with the 5´ and 3´ splice sites are
listed.

Exon
1
2
2a
3
4
5
6
7
8
9
10
11
12
13
14
15

OATP1B3 WT
bases
length(bp)
1-61
61
62-210
149
211-352
353-485
486-607
608-754
755-853
854-1096
1097-1261
1262-1457
1458-1623
1624-1808
1809-1873
1874-1991
1992-2712

142
133
122
147
99
243
165
196
166
185
65
118
721

OATP1B3 V1
bases
length(bp)

1-135
136-277
278-410
411-532
533-679
680-778
779-1021
1022-1186
1187-1382
1383-1548
1549-1733
1734-1798
1799-1916
1917-2637
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135
142
133
122
147
99
243
165
196
166
185
65
118
721

5' Splice site
GTCAAGgtaaga
TTCAAGgtagaa
TAGCAGgtaagg
AAATTGgtaact
GGGATAgtaagt
AAAAAGgtaaga
ATTTAGgtaacg
ATCTGAgtaagt
TGACTGgtaggt
TGTTGGgtaaga
TGATGGgtttgt
CATACAgtgagt
TGTGAAgtaagt
CACTAGgtatga
TTTTGGgtaagt

3' Splice site
taacagGTGATC
ttcttcAGTTAC
ttttagATGTTC
ttctagGAAATT
ttacagTTATAG
cgatagATTGTG
ttacagGTAGTT
tcctagGCACTA
ctatagGTTTTT
ttctagGAATCA
tttcagAAATAA
ttttagGTGTTT
tttcagGATTGT
ttgcagGAGGAA
tcacagAAGGGT

Figure 3. 1 Frequent expression of OATP1B3 V1, a novel splicing variant, in colon
and pancreatic cancer
(A) Schematic representation of OATP1B3 V1 and WT transcripts. Exonic regions are
shown in boxes and translation start and stop codons are marked. (B) Qualitative RT-PCR
analyses show that OATP1B3 V1, but not WT is abundantly expressed in clinical colon
and pancreatic cancer tissues. In contrast, normal liver tissue was shown to express
OATP1B3 WT, but not V1. The primers used amplify the regions encompassing the first

38

and last exons of OATP1B3 V1 or WT. β-actin was used as a loading control. (C)
Quantitative RT-PCR analyses show that OATP1B3 V1 is expressed at varying levels in
the majority of colon and pancreatic cancer cell lines. In contrast, OATP1B3 WT was
detected only in normal liver tissue. Data show the number of OATP1B3 V1 or WT
transcript per 106 copies of β-actin.
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3.3.2 Immunohistochemical Detection of OATP1B3 Variants in Colon and Pancreatic
Cancer
After detecting the mRNA transcript of OATP1B3 variants in the majority of colon and
pancreatic cancer tissues and cell lines, we set out to analyze the protein expression of
OATP1B3 variants in clinical tissues. First, we searched for the possible ORF sequences
of

OATP1B3

variants

(V1

~

V16)

using

an

ORF

finder

(http://www.ncbi.nlm.nih.gov/gorf/gorf.html). For OATP1B3 V1, the search results yielded
many potential ORFs including the longest translated sequence of 674 amino acids. On
the other hand, other variant forms of OATP1B3 (V2 ~ V16) have insertions or deletions
(either in-frame or out-of-frame) at various locations, leading to substantial differences in
the overall peptide sequences compared to OATP1B3 WT. Thus, based on the sequence
similarity to OATP1B3 WT and relative abundance, we chose to focus our investigations
on the V1 isoform. The longest translated product for OATP1B3 V1 utilizes the putative
translation start site (underlined) at the beginning of exon 3 encoding the peptide
sequence MFLAALSFSY at the N-terminus (Fig. 3.2A). The resulting protein is identical
to OATP1B3 WT except lacking 28 amino acids at the N-terminus (Fig. 3.2B). Since our
initial attempt to verify the protein sequence of OATP1B3 V1 using mass spectrometry
was not successful, we developed an antibody detecting the N-terminal sequence (MFL
epitope) of OATP1B3 V1 as an alternative way to verify the peptide sequence of OATP1B3
V1 (Fig. 3.2B). Our immunohistochemical analyses using two polyclonal OATP1B3
antibodies, MFL and SKT produced similar positive cytoplasmic staining patterns in colon
and pancreatic cancer cells (Figs. 3.2C and D). Consistent with the previous findings,
neither MFL nor SKT produced any positive staining in nonmalignant colon and pancreatic
tissue sections (Fig. 3.2C and D). As a control, normal liver tissue sections were also
stained with MFL or SKT (data not shown). Both SKT and MFL antibodies produced
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immunopositive signals around the central veins, which were previously reported to
express high levels of OATP1B3. However, differences in staining patterns were noted;
SKT showed a membranous staining pattern while MFL showed a mainly cytoplasmic
staining pattern. These differences were not entirely surprising given that the MFL epitope
sequence is located in the first transmembrane domain of OATP1B3 WT and may not be
readily accessible for antibody-mediated interactions. As another way of validating the
specificity of MFL, normal liver and colon cancer sections were stained using neutralized
MFL antibody and the results showed that peptide blocking led to substantially attenuated
signals (data not shown). Overall, these results support that the predicted ORF sequence
starting from exon 3 is indeed utilized for translation of the sequence starting with
MFLAALSFSY.
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Figure 3. 2 Immunohistochemical staining of colon and pancreatic cancer tissue
sections using the MFL or SKT antibodies generated against N- or C-terminal tails
of OATP1B3 V1
(A) The sequences of OATP1B3 V1 transcript and translated product. Exons are indicated
and the translation start site located at the beginning of exon 3 is underlined. (B)
Schematic representation of epitope sequences used to develop the antibodies MFL and
SKT. The MFL antibody was generated against MFLAALSFSY located at the N-terminal
tail of OATP1B3 V1. The SKT antibody was generated against SKTCNLDMQDNAAAN
located at the C-terminal tails of OATP1B3 V1 and WT.
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Figure 3. 3 Immunohistochemical staining of colon and pancreatic cancer tissue
sections using the MFL or SKT antibodies generated against N- or C-terminal tails
of OATP1B3 V1
(C & D) Both MFL and SKT antibodies generated similar positive staining patterns in
tissue sections from colon cancer (C) and pancreatic cancer (D). Neither MFL nor SKT
antibodies produced positive staining in non-malignant colon and pancreatic tissue
sections. Cancer tissue sections following the exact procedure except omitting the primary
antibody were included as negative controls.
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3.3.3 Detection of OATP1B3 V1 in Colon and Pancreatic Cancer Cell Lines
In further investigating the expression and function of OATP1B3 V1, we utilized HCT116,
HCT8 and Panc-1 cells expressing varying levels of OATP1B3 V1 (Fig. 3.1C).
Amplification of OATP1B3 V1 using qualitative RT-PCR confirmed expression of the fulllength V1 transcript in HCT116 cells. Additionally, it was noted that HCT116 expressed
higher levels of V1 compared to HCT8 or Panc-1 cells (Fig. 3.3A). Immunoblotting
analyses with the SKT antibody detected OATP1B3 V1 protein at approximately 75 kD
and also demonstrated higher protein expression in HCT116 cells compared to HCT8 and
Panc-1 cells (Fig. 3.3B). We have attempted to use the MFL antibody for immunoblotting,
but our results indicated that the MFL antibody is not suitable due to high background and
non-specific signals.
Using these cell line models, OATP1B3 V1 or WT was transiently expressed by
transfecting the constructs containing the respective ORF and Myc-tag sequences.
Initially, we also included a construct containing the exon 2a sequence prior to the
OATP1B3 V1 ORF and Myc sequence. The resulting protein showed the same
electromobility as that produced from the construct containing the ORF sequence starting
from exon 3, further supporting the usage of the translation start site at the beginning of
exon 3 (data not shown). Interestingly, our immunoblotting results indicated that the
expression level of OATP1B3 V1 is much lower than that of WT in both HCT116 and Panc1 cells despite the same amounts of OATP1B3 V1 or WT constructs used (Fig. 3.3C).
Similar results were obtained in all three cell lines tested (HCT116, HCT8 and Panc-1
cells), even after further increasing the transfected amount of the constructs (data not
shown). In addition, substantial size differences were noted between OATP1B3 V1 and
WT. OATP1B3 V1-Myc was detected at molecular weight above 75 kD, whereas
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OATP1B3 WT-Myc was detected as multiple bands with the most prominent band at
approximately 120 kD (Fig. 3.3C).
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Figure 3. 4 Detection of OATP1B3 V1 in colon and pancreatic cancer cell lines
(A) Qualitative RT-PCR results show the expression of OATP1B3 V1 at varying levels, but
no detectable WT in the cancer cell lines tested. (B) Immunoblotting analyses using SKT
detect the expression of OATP1B3 V1 protein at varying levels in the cancer cell lines
tested. (C) HCT116 and Panc-1 cells were transiently transfected with the constructs
containing the ORF sequences of OATP1B3 V1 or WT fused with Myc tag as well as the
empty vector. Immunoblotting analyses detected the expression of OATP1B3 V1 or WT
proteins with differing electromobility and expression levels. β-actin was used as a loading
control.
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Post-translational modifications such as glycosylation are commonly observed for many
membrane transporters including OATP1B3. Thus, we examined whether the observed
differences in the electromobility of OATP1B3 V1 and WT are due to varying extents of
glycosylation. Following PNGase F treatment, a substantial shift in molecular weight was
seen for OATP1B3WT, which was detected at the expected size of approximately 75 kD
(calculated from 702 amino acids with Myc tag sequence). A similar shift in molecular
weight was also seen for OATP1B3 V1-Myc following the PNGase F treatment, but to a
much lesser extent than OATP1B3 WT (Fig. 3.4A). Taken together, these results suggest
that OATP1B3 V1 is subjected to a much lesser extent of glycosylation, compared to the
WT protein.
Since the exogenous expression of OATP1B3 V1 was much lower than OATP1B3 WT
(Fig. 3.3C), we investigated whether this low expression level of V1 was a result of
decreased protein stability. Following transient transfection, HCT116 cells expressing
OATP1B3 WT or V1 were treated with epoxomicin (a proteasome inhibitor) or ammonium
chloride (a lysosomal inhibitor) (Fig. 3.4B). Epoxomicin treatment led to a substantial
increase in the protein levels of OATP1B3 V1 (especially at higher molecular sizes), but
not OATP1B3 WT. Ammonium chloride treatment had no impact on the protein levels of
OATP1B3 V1 or WT. These results suggest that OATP1B3 V1 may be more susceptible
to proteasomal degradation than OATP1B3 WT.
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Figure 3. 5 Glycosylation and proteasomal degradation of OATP1B3 V1
(A) Immunoblotting analyses were performed using HCT116 lysates transiently
transfected with the constructs, OATP1B3 V1-Myc or WT-Myc. The PNGase F treatment
led to substantial shifts in the electromobility of OATP1B3 V1 and WT, but to a differing
extent. (B) Immunoblotting analyses were performed using lysates prepared from HCT116
cells transiently transfected with the constructs, OATP1B3 V1-Myc or WT-Myc and
subsequently treated with epoxomicin (Epx, a proteasomal inhibitor), ammonium chloride
(A.C., a lysosomal inhibitors) or vehicle alone (DMSO). The epoxomicin treatment led to
a marked increase of the immunoreactive signals of higher molecular sizes, consistent
with accumulation of polyubiquitinated proteins. Neither epoxomicin nor ammonium
chloride treatment influenced the expression of OATP1B3 WT.
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3.3.4 Transporter Activity of OATP1B3 V1 in Colon and Pancreatic Cancer
To investigate whether OATP1B3 V1 functions as an uptake transporter in colon and
pancreatic cancer, we performed cellular uptake studies using [3H]-CCK-8 (a prototype
OATP1B3 substrate) in three cell line models; HCT116 (high endogenous OATP1B3 V1
levels), HCT8 and Panc-1 (low endogenous OATP1B3 V1 levels). Transient expression
of OATP1B3 V1 in these cell lines led to modest increases in the uptake of [ 3H]-CCK-8;
1.4, 2.1 and 2.9-fold increase in HCT116, HCT8 and Panc-1, respectively (Fig. 3.5, upper
panel). Rifampin, a known OATP1B3 inhibitor, effectively inhibited the uptake of [ 3H]CCK-8 in cells transfected with OATP1B3 V1, supporting that the increased [3H]-CCK-8
uptake was likely mediated by OATP1B3-related transport activity. Interestingly,
immunoblotting analysis of OATP1B3 V1 in HCT116, HCT8 or Panc-1 cells showed
slightly different electromobility patterns, possibly related to a varying extent of posttranslational modifications across different cell types (Fig. 3.5, lower panel). In order to
compare the transport activity of OATP1B3 V1 to that of WT, we also examined the uptake
of [3H]-CCK-8 following transient transfection of OATP1B3 WT in the same cell line
models. Considering our observations that the cellular expression levels of OATP1B3 WT
are much higher than those of OATP1B3 V1 following the transfection of the same amount
of constructs (Fig. 3.3C), we reduced the transfected amount of OATP1B3 WT construct
up to 10-fold and verified that the intensity of immunoreactive signals detected using Myc
antibody are comparable between OATP1B3 V1 and WT (data not shown). Our results
indicated that transient expression of OATP1B3 WT markedly increases CCK-8 uptake in
HCT116, HCT8 or Panc-1 cells (41.7, 26.8 and 29.5-fold increase, respectively). In
separate experiments, we also examined whether endogenously expressed OATP1B3 V1
can mediate the uptake of [3H]-CCK-8 using HCT116 cells (high endogenous OATP1B3
V1 levels) with rifampin. The results indicated that there is only a very minor decrease in
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the CCK-8 uptake by rifampin; 2.0 ± 0.8 vs 1.6 ± 0.1 nmol/mg total protein. Taken together,
our results suggest that OATP1B3 V1 has only a modest uptake transporter function in
colon and pancreatic cancer compared to the OATP1B3 WT.
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Figure 3. 6 OATP1B3 V1 shows only a modest increase in cellular uptake of CCK-8
in colon and pancreatic cancer cells
HCT116, HCT8 and Panc-1 cells were transiently transfected with OATP1B3 V1-Myc or
empty vector. When cellular uptake of 3H CCK-8 was compared, the expression of
OATP1B3 V1 led to only a modest (~2-3 fold) increase compared to the empty vector
control. In the bottom panel shown are the immunoblotting results confirming the
OATP1B3 V1 expression for each experiment. Data are represented as percentiles
relative to the empty vector controls. Data are expressed as mean ± SD.
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3.3.5 Subcellular Localization of OATP1B3 V1
To investigate whether the relative inefficiency of OATP1B3 V1 as a transporter was
related to a defective membrane trafficking, we examined subcellular localization of
OATP1B3 V1 by detecting OATP1B3 V1 in the cytoplasmic and membrane fractions
prepared from HCT116 (to monitor endogenously expressed OATP1B3 V1) or HCT8 cells
following transient transfection of OATP1B3 V1 (to monitor exogenously expressed
OATP1B3 V1) using cell surface biotinylation. Our results indicated that OATP1B3 V1
(either endogenous or exogenous) is located abundantly in the cytoplasmic fraction
although a small amount of OATP1B3 V1 was detected in the surface membrane fraction
(Figs. 3.6A and B). These results are in contrast to OATP1B3 WT, which showed a much
stronger signal in the surface membrane fraction than in the cytoplasmic fraction (Fig. 6B).
Of note, OATP1B3 protein in the surface fraction displayed higher apparent molecular
sizes than that in the cytoplasmic fraction (Figs. 3.6A and B). These results are consistent
with a greater extent of post-translation modifications with matured proteins presented to
the surface membrane. Fluorescence microscopy images further verified that OATP1B3
V1 (either Myc-tagged or untagged) is predominantly localized in the cytoplasm of HCT8
cells, while OATP1B3 WT was mainly localized on the plasma membrane (Fig. 3.6C).
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Figure 3. 7 Subcellular localization of OATP1B3 V1 in colon and pancreatic cancer
cells
(A) Surface (S) and cytoplasmic (C) fractions were prepared using HCT116 cells
expressing endogenous OATP1B3 V1. Immunoblotting analyses using SKT show that
OATP1B3 V1 is present in both surface and cytoplasmic fractions. The immunoreactive
band detected in the surface fraction showed a higher apparent molecular size than those
in the cytoplasmic fraction, consistent with a greater extent of post-translational
modifications. (B) HCT8 cells were transfected with the constructs OATP1B3 V1-Myc or
WT-Myc. Similar to the results obtained with HCT116 cells, OATP1B3 V1-Myc was
detected in both surface and cytoplasmic fractions with differing electromobility. In
contrast, OATP1B3 WT-Myc showed much stronger signals in the surface fraction than in
the cytoplasmic fraction, suggesting that OATP1B3 WT is mainly localized in the surface
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membrane. (C) Immunofluorescent images were obtained in HCT8 cells transiently
transfected with OATP1B3 V1-Myc or WT-Myc. Cells transfected with OATP1B3 V1-Myc
showed the immunoreactive signals mainly localized in the cytoplasm. In contrast, cells
transfected with OATP1B3 WT-Myc showed the immunoreactive signals mainly localized
on the surface membrane.
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3.4 DISCUSSION
Despite several reports on the ectopic expression of OATP1B3 across multiple types of
cancer, it is unclear whether OATP1B3 expressed in cancer has biological functions
similar to that in normal liver. In our current study, we demonstrate that colon and
pancreatic cancer cells express variant forms of OATP1B3, different from OATP1B3 WT
expressed in the normal liver. Using OATP1B3 V1, the most prevalent variant lacking 28
amino acids from its N-terminal tail, we show that OATP1B3 V1 has only limited transport
activity and differs from OATP1B3 WT with regard to the extent of post-translational
modifications and subcellular localization. While the mRNA sequence of OATP1B3 V1 is
identical to the one recently reported by Nagai et al. [74], our results provide the first
evidence that the molecular and functional properties of OATP1B3 V1 in cancer differ from
those of OATP1B3 WT. These observed differences need to be taken into account when
further investigating the biological and clinical significance of OATP1B3 variants in cancer.
Using the sequence information of the OATP1B3 V1 transcript, the longest translated
product was predicted to be 674 amino acids. This product utilizes the translation start site
located at the beginning of exon 3 and encodes MFLAALSFSY peptide at the N-terminus.
The previous report by Nagai et al. proposed a translated product of 655 amino acids
starting with MKISITQIE at its N-terminus [74]. This product proposed by Nagai et al.
utilizes the translation start site located further downstream, but in frame with our proposed
translation site (Fig. 3.2A). As a way of verifying the protein sequence of OATP1B3 V1,
we initially attempted to utilize mass spectrometry. However, the results did not provide
adequate protein sequence data, possibly related to the general difficulties associated
with proteomic analyses of membrane-associated proteins [111]. As an alternative
approach, we developed MFL, an OATP1B3 antibody targeting the N-terminal sequence
of OATP1B3 V1. The immunohistochemical analyses showed that the staining patterns
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using MFL were very similar to those obtained using SKT targeting the C-terminal
sequence (Figs. 3.2C and D). These results provide the first evidence for the presence of
the translated product containing the MFLAALSFSY peptide at the N-terminus in clinical
colon and pancreatic cancer tissues. However, we cannot rule out the possibility that other
translated products may exist including the translated products proposed by Nagai et al.
[74] and those from additional OATP1B3 variants identified (data not shown). Of note, it
should be mentioned that MFL may cross-react with OATP1B1, given the close similarity
of the peptide sequences shared between OATP1B3 and OATP1B1 in the N-terminal
region (80% sequence homology). However, the observed positive signals in our tissue
sections are not likely due to OATP1B1 since several reports have indicated that
OATP1B1 is not expressed in colon and pancreatic cancer [3] [4].
With regard to the transport activity, OATP1B3 V1 showed only limited activity for CCK-8
in colon and pancreatic cancer cells, in contrast to OATP1B3 WT which showed a much
higher activity (Fig. 3.5). These findings are consistent with OATP1B3 V1 having less
surface membrane localization compared to OATP1B3 WT (Fig. 3.6). So far little is known
about the mechanisms by which OATP1B3 is localized to the plasma membrane. However,
our results suggest that the missing 28 amino acids at the N-terminal tail of OATP1B3 may
play an important role in membrane trafficking and transporter activity. Interestingly, a
recent study reported that the variant form of human concentrative nucleotide transporter
3 (hCNT3, SLC28A3) missing the N-terminal tail is mainly located in the endoplasmic
reticulum [112]. A follow-up investigation by the same group provided further insights into
the motifs important for surface trafficking of hCNT3 [113]. In nonpolarized cells, acidic
and hydrophobic motifs in the N-terminal tail of hCNT3 were important, whereas a putative
β-turn domain was important in polarized cells. We were not able to locate similar motifs
in the N-terminal tail sequence missing in OATP1B3 V1, but the investigations are on-

56

going to further narrow down sequence segments or motifs important for plasma
membrane trafficking of OATP1B3 WT. Interestingly, our current results showed that the
expression of OATP1B3 V1 leads to statistically significant increases in the CCK-8 uptake
in HCT8 and Panc-1 cells (polarizable cell lines), but not in HCT116 cells (non-polarizable
cell line) (Fig. 3.5). Thus, it remains to be determined if OATP1B3 variants are
preferentially localized in certain intracellular organelles and whether localization patterns
or transport activity of OATP variants would depend on the polarizing ability or status.
Although we observed major differences in the membrane trafficking between OATP1B3
V1 and WT, it should be noted that alternative mechanisms (e.g. differences in posttranslational modifications, mRNA/protein stability) may contribute to the limited transport
activity of OATP1B3 V1.
In our current study, we observed that OATP1B3 V1 localized mainly in the cytoplasm has
only limited transporter function in colon and pancreatic cancer. Although alternative
splicing is increasingly recognized as a common event in eukaryotic cells, the abundance
of OATP1B3 variants across multiple types of cancer argues for this protein being
selectively generated for a purpose. Previously, we suggested that OATP1B3 may confer
a survival advantage in colorectal cancer cells via p53-dependent pathways [6]. However,
at that time, the presence of OATP1B3 V1 was not known and the studies were performed
using the OATP1B3 WT sequence. We are currently investigating whether OATP1B3 V1
may have other biological functions, especially its potential as an antiapoptotic or
prosurvival protein. In the literature, several reports indicate that membrane transporters
may have functions independent of their transport activity. For example, P-glycoprotein
(Pgp) encoded by the MDR1 gene was shown to be localized intracellularly in several
human leukemia, breast cancer and hepatoma cell lines [114, 115], [116, 117] and to serve
as an anti-apoptotic protein in several types of cancers [118-123]. In particular, Pgp was
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able to suppress apoptosis even in the absence of ATP-dependent drug efflux, suggesting
that the antiapoptotic function of Pgp may be independent of its transporter activity [123].
Alternative splicing is increasingly recognized as a mechanism that generates protein and
functional diversity and there are a number of reports on the splicing variants of membrane
transporters. In particular, the expression of alternative mRNA transcripts of murine
oatp1b2, an ortholog for both human OATP1B3 and OATP1B1, has been reported [56].
These alternative transcripts of oatp1b2 show quite different splicing patterns with human
OATP1B3 variants, in that they share the same transcription start site as oatp1b2 WT, but
lack the exonic sequences located in the middle region. The presence of alternative
transcripts has also been reported with other human transporters such as OAT2 [124] and
OATP3A1 [125]. However, the presence of cancer-specific variants appears to be unique
for OATP1B3. In particular, no cancer-specific variants have been reported with OATP1B1
which shares more than 70% sequence homology and numerous substrates with
OATP1B3. An effort to examine the mechanisms by which the cancer-specific expression
of OATP1B3 variants is achieved may be warranted.
In conclusion, we report that colon and pancreatic cancer cells express variant forms of
OATP1B3 mRNA and protein. OATP1B3 V1, the most prevalent form, appears to lack a
full transport activity compared to OATP1B3 WT. Our results indicate that OATP1B3 V1
is located mainly in the cytoplasm and the extent of plasma membrane trafficking was
much lower in OATP1B3 V1 than in WT. Although the biological significance of OATP1B3
variants in cancer is yet to be defined, our findings should be taken into consideration
when further exploring the potential role of OATP1B3 expressed in cancer.
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Chapter 4
Role of Hypoxia Inducible Factor-1α in the Regulation of the Cancer-Specific
Variant of Organic Anion Transporting Polypeptide 1B3 (OATP1B3)
in Colon and Pancreatic Cancer
(The work in this chapter has been published in Biochemical Pharmacoloy (2013) [77])
4.1 Introduction
Organic Anion Transporting Polypeptide 1B3 (OATP1B3) belongs to the superfamily of
OATP transporters and mediates the hepatic uptake of various endogenous and
xenobiotic compounds [2]. Although OATP1B3 was initially considered to be a liverspecific transporter, subsequent investigations revealed that OATP1B3 is also expressed
in human cancers derived from multiple organs including colon, pancreas, prostate, breast
and lung [3, 5-9, 67, 110, 126, 127]. Considering that OATP1B3 is not detected in any
other non-malignant tissues except the liver, a question was raised whether or not
OATP1B3 expression in cancer has any pathogenic and functional significance. Recently,
our group and others reported the distinct identity of OATP1B3 expressed in cancer cells,
namely cancer-specific OATP1B3 variants (csOATP1B3) that utilize an alternative
transcription initiation site and lack the first two exons of the wild-type (WT) OATP1B3
expressed in the normal liver [73, 128]. Our previous investigations focused on
csOATP1B3 V1, the most prevalent cancer-specific variant form and reported that
csOATP1B3 V1 lacking the N-terminal 28 amino acids displays only a modest transport
activity and a defective membrane trafficking compared to OATP1B3 WT [73]. While
further investigations are under way to better understand the functional significance of
csOATP1B3, the molecular mechanisms underlying the expression of csOATP1B3 may
provide important clues about the role of csOATP1B3 in cancer.
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Hypoxia arises from an imbalance between the supply and consumption of oxygen and it
is recognized as a characteristic feature of locally advanced solid cancers [129-131]. In
multiple types of cancers, hypoxia has been associated with adverse clinical outcomes
including cancer cell invasion and metastasis [129-133]. Adaptation to the hypoxic
environment involves changes in the expression of numerous genes encoding
erythropoietic, vasoactive, and proangiogenic molecules and metabolic enzymes [131]. A
crucial component in the induction of hypoxia-regulated genes is the hypoxia inducible
factor-1 (HIF-1) complex, composed of HIF-1α and HIF-1β subunits. While the HIF-1β
subunit (also known as aryl hydrocarbon nuclear translocator, ARNT) is constitutively
expressed, the HIF-1α subunit is accumulated only under hypoxic exposure by escaping
proteasome-mediated degradation [134, 135]. Under the hypoxic conditions, the HIF-1α/β
heterodimer is translocated to the nucleus and binds to a specific cis-acting regulatory
sequence referred to as the hypoxia response element (HRE) in target genes, thereby
causing transcriptional activation.
Interestingly, a previous report by Winter et al. [10] suggested a possible link between
hypoxia and the expression of OATP1B3 in cancer cells. In the process of defining an in
vivo hypoxia gene signature (hypoxia metagene) in head and neck cancer, the authors
found SLCO1B3 encoding OATP1B3 among the highly upregulated genes under hypoxia
[10]. This hypoxia metagene including SLCO1B3 was associated with adverse outcomes
in patients with head and neck cancer as well as breast cancer [10]. Since the presence
of csOATP1B3 was not known at the time of publication of this report, it remained unknown
whether hypoxia induces the expression of csOATP1B3, OATP1B3 WT or both.
Using colon and pancreatic cancer cells, our current study establishes that hypoxia
induces the expression of csOATP1B3, but not OATP1B3 WT. In addition, we report that
the csOATP1B3 promoter contains a functional HRE, which the HIF-1α protein binds to.
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Selective knockdown of HIF-1α also decreased the basal expression level of csOATP1B3
and attenuated the extent of csOATP1B3 induction by hypoxia. Taken together, the
current findings described in this chapter demonstrate that the transcription of csOATP1B3
is actively engaged during hypoxia, via a HIF-1α-dependent mechanism.
4.2 Materials and Methods
4.2.1 Cell culture and hypoxic treatments
Human cancer cell lines derived from colon (Caco-2, SW480, HCT-8, DLD-1, and HCT116)
and pancreas (AsPC-1, MiaPaCa-2, and BxPC-3) were obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and maintained in the recommended conditions.
For hypoxic treatment, cells at approximately 50% confluence were placed in a hypoxic
chamber maintaining 1% O2, 5% CO2 and 94% N2 or exposed to CoCl2, a chemical inducer
of HIF-1α for the time periods indicated. The medium was replaced every 24 h during
hypoxic exposure.
4.2.2 RT-PCR
Single-stranded cDNA was synthesized from 1 µg of total RNA using the SuperScriptTM III
cDNA synthesis kit (Invitrogen, Carlsbad, CA). To examine the presence of full-length
transcripts (spanning from the first to the last exons) of OATP1B3 WT or csOATP1B3 V1
in the resulting cDNA samples, RT-PCR was performed using Platinum® Supermix
(Invitrogen, Carlsbad, CA) and the previously reported primers; OATP1B3 WT (exons 115, expected size: 2214 bp) or csOATP1B3 V1 (exons 2a-15, expected size: 2077 bp)
[73]. In order to examine the effect of hypoxia on other OATP members closely related to
OATP1B3, RT-PCR analyses of OATP1A2 and OATP1B1 transcripts were performed
using the following primers; for OATP1A2, sense (5’-ATGGGAGAAACTGAGAAAAG-3’)
and anti-sense (5’- GCATGTTCTCTAATTCTGAA-3’); for OATP1B1, sense (5’-

61

TGAACACCGTTGGAATTGC-3’) and anti-sense (5’-TCTCTATGAGATGTCACTGGAT3’). PCR products were visualized on 1% agarose gel. Band intensities were
densitometrically quantified using the Quantity One software (Bio-Rad, Hercules, CA) and
normalized using the band intensities of the housekeeping control β-actin.
4.2.3 Immunoblotting analysis
Cell lysates were prepared in lysis buffer (10 mM Tris, 150 mM NaCl, 1% sodium
deoxycholate, 0.1% SDS, 1% Triton X-100, pH 7.4) containing protease inhibitors (Roche,
Mannheim, Germany). To minimize the formation of protein aggregates, cell lysates were
incubated at room temperature for 30 min after mixing with 4x Laemmli buffer. Equivalent
amounts of total protein were resolved by SDS-PAGE and subsequently transferred to
PVDF membranes. After blocking with 5% skim milk prepared in Tris-buffered saline
containing 0.5% Tween 20, the membranes were incubated overnight with the following
primary antibodies: OATP1B3 (SKT; generated against the C-terminal epitope and
validated previously [73, 136]), HIF-1α (BD Biosciences, San Jose, CA), β-actin (Cell
Signaling, Danvers, MA). The immunoreactive proteins were detected using a secondary
antibody conjugated with horseradish peroxidase purchased from Cell Signaling
(Danvers, MA) and an enhanced chemiluminescence substrate purchased from Pierce
(Rockford, IL). Band intensities were densitometrically quantified using the Quantity One
software (Bio-Rad, Hercules, CA) and normalized using the band intensities of the gel
loading control β-actin.
4.2.4 Construction of plasmid vectors
The promoter region upstream of the first exon of OATP1B3 WT (−2023 to +100) or
csOATP1B3 (−1853 to +151) was amplified by PCR using a BAC clone (RP11-269H12,
Empire Genomics, Buffalo, NY) as a template. The amplified DNA was subcloned into
pGL4.1 (Promega, Fitchburg, WI), and termed as OATP1B3 WT (-2023) and csOATP1B3
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(-1853), respectively. The 5-deletion constructs of the csOATP1B3 promoter were
prepared by subcloning the PCR products using the specific primers into pGL4.1. The
resulting constructs were termed as csOATP1B3 (-1053), csOATP1B3 (-553),
csOATP1B3 (-263), respectively. The csOATP1B3 (-263)-mut-HRE construct was created
by mutating the putative HRE located at +23 - +27 (from 5′-ACGTG-3′ to 5′-AAAAG-3′)
using a site-directed mutagenesis kit obtained from Stratagene (Wilmington, DE). The
sequences of each of the prepared plasmids was verified by direct sequencing.
4.2.5 Reporter assay
HCT-8 cells were plated onto 24 well plates and transfected with the reporter plasmid (360
ng/well) along with pRL-TK (40 ng/well, an internal control obtained from Promega,
Fitchburg, WI). Twenty-four hours after transfection, the cells were exposed to either CoCl2
(100 or 200 µM) or hypoxia (1% O2) for another 24 h. After extensive washing with
phosphate-buffered saline, cells were harvested and firefly and Renilla luciferase activities
were determined using the Dual Luciferase Reporter Assay kit (Promega, Fitchburg, WI)
and a Veritas microplate luminometer (Turner Biosystems, Sunnyvale, CA). The data were
plotted using GraphPad Prism 5.04 (La Jolla, CA).
4.2.6 Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from HCT-8 cells following the treatment with CoCl2 (200
μM, 24 h) as reported previously [137]. Briefly, binding reactions were prepared in tubes
containing 6 μg of nuclear extracts, 1.25 μg of Poly(dI-dC), 7.5 μl binding buffer (containing
20 mM HEPES, pH 7.9, 1 mM DTT, 0.1 mM EDTA, 50 mM KCl, 5 % glycerol, and 200
μg/μl bovine serum albumin) and water adjusted to make the final reaction volume of 20
μl. The binding reactions were carried out for 10 min on ice. Subsequently, the biotinylated,
annealed probe containing the HRE of the csOATP1B3 promoter (5’-Biotintriethyleneglycol-CATCTCGGCGTATACGTGCAAGTCACAG-3’, synthesized by MWG
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Biotech, Huntsville, AL) was added to the binding reaction mixtures and further incubated
for 20 min at room temperature. For competition experiments, a 200-fold excess of the
unlabeled, annealed probe was added to the reaction mixture. DNA-protein complexes
were resolved by 4.5% polyacrylamide gel electrophoresis run at 4 C. Signals from the
biotinylated probe on the gel were detected using the EMSA gel shift Kit obtained from
Affymetrix (Santa Clara, CA) according to the manufacturer’s instructions. The sequences
for the oligonucleotide probes with the intact HRE or mutated HRE sites as well as a
consensus HRE probe (a positive control from the endothelin-1 gene [138]) were as
follows;

csOATP1B3

csOATP1B3-mut-HRE

probe,

5-

probe,

CATCTCGGCGTATACGTGCAAGTCACAG-3;
5-CATCTCGGCGTATAAAAGCAAGTCACAG-3;

consensus HRE probe, 5-AGCTTGCCCTACGTGCTGTCTCAGA-3.
4.2.7 siRNA-mediated knockdown of HIF-1α
Cells were transfected with siRNA duplexes targeting HIF-1α (pooled siRNA, Dharmacon,
Lafayette, CO) or control scrambled siRNA (Santa Cruz biotechnology, Dallas, TX) using
Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA), according to the
manufacturer’s protocol. The mRNA and protein levels of HIF-1α and csOATP1B3 were
analyzed 48 hours after transfection.
4.3 Results
4.3.1. Impact of hypoxia on the expression of csOATP1B3 in human colon and pancreatic
cancer cell lines
We assessed a potential association between csOATP1B3 and HIF-1α by comparing the
endogenous expression levels of csOATP1B3 V1 and HIF-1α in a panel of human colon
and pancreatic cancer cell lines (Fig. 4.1). Our results indicated that the cell lines
expressing detectable levels of csOATP1B3 V1 (i.e., DLD-1, HCT116, BxPC-3, MiaPaCa-
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2) display HIF-1α protein accumulation. In contrast, the cell lines lacking csOATP1B3 V1
(i.e. Caco-2, SW480, HCT-8, AsPC-1) did not have any detectable levels of HIF-1α. This
apparent association between csOATP1B3 and HIF-1α accumulation prompted us to
further probe the involvement of HIF-1α in regulating the csOATP1B3 expression.
Using MiaPaCa-2 and HCT116 cell lines expressing detectable levels of csOATP1B3, we
initially examined the effect of hypoxia (1% O2) on csOATP1B3 expression levels. Our
results show that hypoxia leads to a modest increase in csOATP1B3 levels in MiaPaCa2
cells, but not in HCT116 cells (Fig. 4.2A). Of note, OATP1B3 WT was detected in neither
MiaPaCa-2 nor HCT116 cells, regardless of hypoxia treatment. In order to examine the
cell line-dependency of the hypoxia effect on csOATP1B3 expression, we also performed
similar experiments using HCT-8 cells. In HCT-8 cells, hypoxia markedly increased the
levels of both HIF-1α and csOATP1B3 in a time-dependent manner (Fig. 4.2B). However,
there were no hypoxia-induced changes in the levels of OATP1B1 or OATP1A2 in HCT-8
cells (Fig. 4.2B).
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Figure 4. 1 Expression of csOATP1B3, OATP1B3 WT and HIF-1α in human colon
and pancreatic cancer cell lines
(A) Schematic representation of the transcripts for csOATP1B3 V1 and OATP1B3 WT.
The sequence of csOATP1B3 V1 differs from that of OATP1B3 WT, in that it contains the
alternative exonic sequence (termed as exon 2a) instead of exons 1 and 2. Arrows
represent the landing sites of primers used for amplification of OATP1B3 WT (exons 1-15)
or csOATP1B3 (exons 2a-15). (B) RT-PCR and immunoblotting results showing varying
levels of endogenous csOATP1B3 and HIF-1α expression in human colon (Caco-2,
SW480, HCT-8, DLD-1, HCT116), pancreatic cell lines (AsPC-1, MiaPaCa-2, BxPC-3)
and normal liver tissue. β-actin was used as a housekeeping control. Relative band
intensities normalized to β-actin are represented as arbitrary units (AU).
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Figure 4. 2 Hypoxia leads to upregulation of csOATP1B3, but not OATP1B3 WT
(A) MiaPaCa-2 and HCT116 cells exposed to normoxia (Nor) or hypoxia (1% O2, Hyp) for
48 h. (B) HCT-8 cells were exposed to hypoxia for 0, 8 and 24 h. RT-PCR analyses were
performed to determine the expression level of csOATP1B3, OATP1B3 WT, OATP1B1 or
OATP1A2. Immunoblotting analyses were performed to detect HIF-1α protein. β-actin was
used as a housekeeping control Relative band intensities normalized to β-actin are
represented as arbitrary units (AU).
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4.3.2. Effects of hypoxia on the transactivation of csOATP1B3 promoter and identification
of a functional HRE
Based on our results showing hypoxia-induced upregulation of csOATP1B3 in HCT-8
cells, we investigated whether the mechanism involves transcriptional activation. We
performed in silico analyses of the csOATP1B3 promoter sequence, in search for any
putative cis-acting elements responsive to hypoxia. Our results using the MatInspector
database (Genomatix Software Inc, Ann Arbor, MI) indicated the presence of a putative
HRE located within Exon 2a (Fig. 4.3A). In further validating the DNA sequences involved
in the csOATP1B3 transactivation, we utilized a hypoxia mimetic agent CoCl2 [139]. As
expected, the exposure of HCT-8 cells to CoCl2 led to a marked increase in the HIF-1α
and csOATP1B3 levels, with no changes in the levels of OATP1B3 WT, OATP1B1 and
OATP1A2 observed (Fig. 4.3B). These findings are consistent with those obtained using
ambient hypoxia (Fig. 4.2B).
We then determined the effect of CoCl2 treatment on the promoter activity of csOATP1B3
or OATP1B3 WT, using the reporter constructs of csOATP1B3 (-1853) and OATP1B3 WT
(-2023) (Fig. 4.3A). The results indicated that CoCl2 treatment increases the reporter
activity of the csOATP1B3 (-1853), but not that of the OATP1B3 WT (-2023) (Fig. 4.3C).
To further narrow down the cis-elements responsible for the hypoxia-mediated
transactivation of csOATP1B3 promoter, we compared a series of 5-end deletion mutants
for their extent of activation by CoCl2. Our results indicate that all three deletion mutants
and the csOATP1B3 (-1853) construct were comparable in their extent of CoCl2-induced
transactivation (Fig. 4.3C). Using the smallest construct csOATP1B3 (-263), we prepared
a construct where the putative HRE sequence is mutated. The csOATP1B3 (-263)-mutHRE construct showed no increase in the reporter activity following the exposure to CoCl2
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treatment (Fig. 4.3C) or 1% O2 (Fig. 4.3D). These results suggest that the putative HRE
site may be responsible for the hypoxia-induced transactivation of csOATP1B3.
To determine whether HIF-1α indeed binds to the putative HRE in the csOATP1B3
promoter, EMSA was performed using the probe containing the putative HRE of
csOATP1B3. Nuclear extracts isolated from HCT-8 cells treated with CoCl2 (200 μM, 24
h) produced a unique band shift (Fig. 4.4, indicated by an arrow). This shift was competed
away by unlabeled probe containing the intact HRE, but not by the unlabeled probe
containing the mutated HRE (Fig. 4.4). As a positive control, a previously validated
consensus HRE sequence from the endothelin-1 gene [138] was used and produced a
similar band shift when incubated with the same nuclear extract. These results suggest
that HIF-1α can physically interact with the HRE site in the csOATP1B3 promoter.
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Figure 4. 3 Hypoxia-induced transactivation of csOATP1B3 promoter
(A) Schematic representation of the reporter constructs containing the promoter
sequences for OATP1B3 WT or csOATP1B3. A consensus hypoxia-responsive element
(HRE) present in exon 2a (underlined) is shown along with the mutated HRE sequence
used in subsequent experiments. (B) Effect of CoCl2, a hypoxia mimetic agent on the
expression of csOATP1B3 and HIF-1α. HCT-8 cells exposed to CoCl2 (100 or 200 µM, 24
h) were analyzed for the expression of csOATP1B3, OATP1B3 WT, OATP1B1, OATP1A2
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and HIF-1α via RT-PCR and immunoblotting. (C) Effects of chemical hypoxia on the
promoter activity using various reporter constructs of csOATP1B3 or OATP1B3 WT. The
extent of CoCl2-induced transactivation was compared among various promoter
constructs following the transient transfection in HCT-8 cells and subsequent treatment
with CoCl2 (200 μM, 24 h). (D) Effects of ambient hypoxia on the promoter activity using
various reporter constructs of csOATP1B3 promoter. The extent of hypoxia-induced
transactivation was compared among various promoter constructs following the transient
transfection in HCT-8 cells and subsequent exposure to 1% O2 (24 h). Experiments were
performed in triplicates, and their values are expressed as mean ± S.D.
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Figure 4. 4 Electrophoretic mobility shift assay (EMSA) results showing that HIF-1α
binds to a hypoxia response element (HRE) in the csOATP1B3 promoter
Nuclear extracts from HCT-8 cells exposed to CoCl2 (200 μM, 24 h) show a specific band
shift when incubated with the biotinylated csOATP1B3-HRE probe or a consensus HRE
probe (indicated by the arrow). The band shift was competed away by an excess of
unlabeled csOATP1B3-HRE probe, but not by an excess of unlabeled csOATP1B3-mutHRE probe where the consensus HRE is mutated.
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4.3.3. Effects of HIF-1α knockdown on csOATP1B3 expression
In order to further validate the role of HIF-1α on csOATP1B3 expression, we examined
the effect of siRNA-based HIF-1α knockdown on the csOATP1B3 levels in HCT-8 cells
exposed to hypoxia and additional cell lines expressing basal levels of csOATP1B3. The
extent of csOATP1B3 upregulation by CoCl2 was substantially reduced in HCT-8 cells
transfected with siRNA targeting HIF-1α, compared to those transfected with control
siRNA (Fig. 5A). The siRNA-based HIF-1α knockdown also led to down-regulation of
csOATP1B3 at both the mRNA and the protein levels in HCT116 cells expressing high
basal levels of HIF-1α and csOATP1B3 (Fig. 5B). Similar results were obtained using
additional cell lines (DLD-1 and BxPC-3 cells, data not shown).

73

Figure 4. 5 HIF-1α knockdown decreases the expression of csOATP1B3
(A) The siRNA-based HIF-1α knockdown leads to a marked decrease in the extent of
csOATP1B3 upregulation in HCT-8 cells exposed to CoCl2. (B) The siRNA-based HIF-1α
knockdown markedly decreases csOATP1B3 levels in HCT116 cells. β-actin was used as
a housekeeping control Relative band intensities normalized to β-actin are represented as
arbitrary units (AU).
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4.4 Discussion
Alternative splicing is recognized as a common, yet important event of adding diversity in
the proteomic world of eukaryotic cells. For an increasing number of membrane efflux and
influx transporters including Oatp2 (the rodent ortholog of OATP1B3), the presence of
alternatively spliced transcripts has been reported [125, 140-144]. Many of these splicing
variant products have been detected in the organs or cell types normally expressing their
WT transcripts. In contrast, the recently identified splicing variants of OATP1B3 are
detected only in cancer settings and do not coexist with the WT OATP1B3 [73, 128]. These
findings led us to hypothesize that the expression of csOATP1B3 may be influenced by
oncogenic signaling pathways and may have potential roles in cancer development and
progression. Following up on the previous reports suggesting a potential link between
hypoxia and OATP1B3 expression in cancer [10, 145], our current study further
investigated the regulatory mechanisms underlying hypoxia-induced upregulation of
OATP1B3 in cancer. Our current findings provide evidence that hypoxia can induce the
expression of csOATP1B3, but not OATP1B3 WT and that HIF-1α plays an important role
in regulating csOATP1B3 expression in colon and pancreatic cancer cells. Further
investigations would be necessary to address the relative importance of this HIF-1αdependent mechanism on csOATP1B3 expression in clinical cancer tissues, in particular,
in comparison to other reported mechanisms [76]. Our findings provide for the first time a
mechanistic understanding of the csOATP1B3 regulation in colon and pancreatic cancer
and underline the rationale for the investigation of functional and pathogenic significance
of csOATP1B3.
HIF-1α is often accumulated in multiple types of human cancers derived from lung, breast,
prostate and gastrointestinal tissues [45, 146-150]. For colon and pancreatic cancer, it has
been reported that HIF-1α expression is predictive of poor prognosis and short disease-
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free survival [151-154]. This association of HIF-1α with clinical outcomes has been often
attributed to subsequent changes in downstream effectors important in tumor growth and
survival as well as tumor metabolism [131, 148, 155]. Currently, it is not known whether
csOATP1B3 serves as one of downstream effectors of the HIF-1α pathway, potentially
providing tumor growth/survival advantages. In that regard, our laboratory had previously
reported that OATP1B3 may serve as an antiapoptotic or prosurvival protein in colorectal
cancer cells [6]. However, such findings were obtained using cancer cell line models stably
transfected with OATP1B3 WT, as the presence of csOATP1B3 was not known at that
time. Given the close sequence similarity (~96%) of the csOATP1B3 and OATP1B3 WT
(amino acid sequence of csOATP1B3 V1 identical to OATP1B3 WT except missing Nterminal 28 amino acids), it is plausible that csOATP1B3 may confer apoptotic resistance
or growth advantage in a similar manner to OATP1B3 WT. Supporting such a possibility,
Ramachandran et al. [145] recently reported that selective knockdown of OATP1B3
expressed in colorectal cancer cell lines leads to a decrease in cell size and 3-dimensional
spheroid volume. Similarly, Silvy et al. [156] reported that OATPs expressed in human
melanoma cells may reduce the anticancer activity of cisplatin in a protein kinase Cdependent manner. Using clinical pancreatic cancer tissues and precancerous lesions, a
recent report also suggested that OATP1B3 can serve as a potential diagnostic marker
for early stage pancreatic cancer [127]. These findings are certainly intriguing and warrant
further investigations to verify the functional roles and prognostic/predictive implications
of csOATP1B3 in colon and pancreatic cancer.
Our current findings provide evidence for the involvement of HIF-1α in regulating
csOATP1B3, but it is possible that other regulatory mechanisms may play a role in the
expression of csOATP1B3. A previous report by Ichihara et al. demonstrated that
OATP1B3 expression in cancer cell lines can be upregulated by the treatment with the
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DNA-methylating agent, 5-aza-2’-deoxycytidine (5-Aza), suggesting the involvement of
DNA-methylation based gene-silencing in the regulation of OATP1B3 expression [76]. We
briefly examined whether the exposure of HCT-8 cells to 5-Aza induces the expression of
csOATP1B3, OATP1B3 or both. Our results indicated that 5-Aza treatment leads to an
increase in the level of csOATP1B3, but not OATP1B3 WT (unpublished data). Although
not directly tested for the case of csOATP1B3 regulation, there exists evidence suggesting
interplay among hypoxia, epigenetic modulation, and alternative splicing. For instance, it
has been reported that hypoxia can influence cellular epigenetic status and that DNA
demethylation can augment hypoxia-induced effects by positive auto-regulation of HIF-1α
[157, 158]. A recent report also suggested that DNA methylation status of a HRE sequence
can influence the interactions of HIF-1α with the HRE site, subsequently the hypoxic
inducibility of the target gene [159]. More intriguingly, it was reported that HIF-1 proteins
may regulate alternative splicing of many target genes [160]. For better understanding of
csOATP1B3 regulation, further investigations are necessary to explore the interplay
between different regulatory mechanisms.
In conclusion, we report for the first time that csOATP1B3, but not OATP1B3 WT, is
transcriptionally regulated in response to hypoxia in colon and pancreatic cancer. Our
results identified a functional HRE site in the csOATP1B3 promoter that physically
associates with HIF-1α. Our data suggests that HIF-1α may play a key role in regulation
of csOATP1B3 in colon and pancreatic cancer cells. Our findings may provide important
clues about the functional and clinical significance of csOATP1B3 in colon and pancreatic
cancer

Copyright © Nilay Thakkar 2015
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Chapter 5

Roles of N-terminal motifs in plasma membrane trafficking of Organic Anion
Transporting Polypeptide 1B3 (OATP1B3)

5.1 INTRODUCTION
Organic anion transporting polypeptide 1B3 (OATP1B3) belongs to the OATP (gene
symbol SLCO) superfamily of solute carriers. OATP1B3 is abundantly expressed in the
hepatocytes and mediates the transmembrane uptake of a variety of endogenous and
xenobiotic substances. The endogenous substrates of OATP1B3 include bile salts, steroid
hormone conjugates, thyroid hormone, peptides and natural toxins phalloidin and
microcystin-LR [3, 4, 67]. OATP1B3 plays an important role in the disposition of several
important therapeutic agents including cholesterol-lowering statins, anti-cancer drugs,
antibiotics, cardiac glycosides and antidiabetics [4, 161]. In recent years, OATP1B3 is
identified as an important determinant of transporter-mediated drug interactions [162].
Despite the increasingly recognized importance of OATP1B3 in drug therapy, little is
known about the mechanisms regulating the intracellular trafficking of OATP1B3. Similar
to other members of OATP superfamily, OATP1B3 is predicted to have 12 transmembrane
domains (TMs) [2]. A previous study reported that TM10 of OATP1B3 is important for the
recognition of the OATP1B3-specific substrate cholecystokinin-8 (CCK-8) [163]. These
findings were based on the results obtained using a series of chimeric proteins between
OATP1B3 and its closely related family member, OATP1B1 [163]. Other investigations
probed the contribution of individual amino acids on the transport activity and membrane
trafficking of OATP1B3 using the constructs harboring point mutations at several
conserved positions (K41, K361, K399 and R580 located in the TMs 1, 7, 9 and11,
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respectively) [164, 165]. Overall, our understanding of intracellular trafficking processes
of OATP1B3 remains to be limited.
Our laboratory and others have recently reported the identity of a cancer-specific
OATP1B3 variant which utilizes an alternative transcription initiation site and lacks the Nterminal 28 amino acids [73-75]. In contrast to the wild-type (WT) OATP1B3 expressed in
normal liver, the cancer-specific variant was found to be localized predominantly in the
cytoplasm [73]. These findings provided us an interesting clue that the N-terminus of
OATP1B3 may play an important role in regulating its intracellular trafficking. Here, we set
out to follow up on our previous observations and further identify N-terminal motifs
important for regulation of the expression and membrane trafficking of OATP1B3. Utilizing
the sequential truncation and point mutation approaches, we report that the N-terminal
region at amino acid positions 14 to 17 with a putative β-turn-forming tetrapeptide is
important for regulating the expression and membrane localization of OATP1B3.
5.2 MATERIALS AND METHODS
5.2.1 Chemicals and Reagents
Sodium butyrate and poly-lysine hydrobromide were purchased from Sigma-Aldrich. [3H]Cholecystokinin-8 ([3H]-CCK-8, 104.2 Ci/nmol, >90% purity) was purchased from PerkinElmer.
5.2.2 In-silico analyses for potential signaling motifs at the N-terminal region of OATP1B3
In-silico algorithms such as PROSITE, CLOUDES, and BetaTPred were utilized to predict
the potential amino acids motifs involved in cellular signaling and processing of
OATP1B3[113]. The propensity of forming β-turn tetrapeptides (Δ scores) was calculated
using the previously published method by Chou [166] .
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5.2.3 Construction of expression plasmids for truncation and point mutants of OATP1B3
at the N-terminus
The expression plasmid for WT OATP1B3 containing the ORF sequence fused with Myc
tag sequence at the C-terminus was purchased from Origene [73]. Truncation mutants of
OATP1B3 were generated by swapping the incrementally truncated sequences which
were PCR amplified with the restriction sites SgfI and PacI using the primers listed in Table
5.1. The insertion of the corresponding sequences (represented as Δ11, Δ23 and Δ28
respectively) was verified by direct sequencing. The expression plasmids for point mutants
of OATP1B3 were prepared using QuikChange® site-directed mutagenesis (SDM) kit
(Agilent) and the primers listed in Table 5.1. Direct sequencing was performed to verify
whether the correct point mutation was introduced.
5.2.4 Cell culture and plasmid transfection
Human colon cancer cell lines HCT116 and HCT8 were purchased from American Type
Culture Collection (ATCC). HEK293 cells were kindly provided by Dr. Markos Leggas
(University of Kentucky). For expression and functional investigations, OATP1B3 and
mutants were transiently transfected using Lipofectamine 2000 (Invitrogen) (for HCT116
and HEK293 cells) or Fugene HD (for HCT8 cells). Protein expression analyses and
transport experiments were typically carried out 48 h after transfection. Initially comparable
transfection efficiencies of the truncation and SDM constructs were verified by checking
green fluorescence signals following co-transfection of a separate plasmid expressing
green fluorescent protein (GFP).
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Table 5.1: Primer sequences and combinations for generation of OATP1B3
truncation and point mutants

Construct

Sequence (5’-3’)

Restriction
site(s)

OATP1B3 Δ11
OATP1B3∆23
OATP1B3∆28
OATP1B316AA17

CGATGCGATCGCATGGAGTCAGCATCTT (Fw)

Sgf1

CCATTGAATGATAAGGTTTGATTAATTAAACAGG(Rv)

Pac1

CGATGCGATCGCATGTGCAATGGATTCA (Fw)

Sgf1

CCATTGAATGATAAGGTTTGATTAATTAAACAGG(Rv)

Pac1

CGATGCGATCGCATGTTCTTGGCAG (Fw)

Sgf1

CCATTGAATGATAAGGTTTGATTAATTAAACAGG(Rv)

Pac1

GCAGAGTCAGCATCTGCAGCGAAAAAGAAAACAAGACGC (Fw)

GCGTCTTGTTTTCTTTTTCGCTGCAGATGCTGACTCTGC (Rv)
OATP1B3S13A

GAATAAAACAGCAGAGGCAGCATCTTCAGAGAAAAAG (Fw)
CTTTTTCTCTGAAGATGCTGCCTCTGCTGTTTTATTC (Rv)

OATP1B3S15A

AAAACAGCAGAGTCAGCAGCTTCAGAGAAAAAGAAAAC (Fw)
GTTTTCTTTTTCTCTGAAGCTGCTGACTCTGCTGTTTT (Rv)

OATP1B3S16A

CAGCAGAGTCAGCATCTGCAGAGAAAAAGAAAACAAG (Fw)
CTTGTTTTCTTTTTCTCTGCAGATGCTGACTCTGCTG (Rv)
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5.2.5 Immunoblotting analyses
Cell lysates were prepared using the lysis buffer (containing 10 mM Tris, 150 mM NaCl,
1% Sodium deoxycholate, 0.1% SDS, 1% Triton X-100, pH 7.4) containing protease
inhibitors (cOmplete, Roche). Cell lysates were mixed with 4X Laemmli buffer and
incubated at room temperature for 30 min. Cell lysates containing equivalent protein
amounts were separated by SDS-PAGE and transferred to a PVDF membrane. After
blocking, the membranes were incubated overnight with a primary antibody against Myc
tag or β-actin (Cell signaling). The immunoreactive proteins were detected using a
secondary antibody conjugated with horseradish peroxidase and an enhanced
chemiluminescence substrate (Pierce).
5.2.6 Radioactive uptake assay
[3H]-Cholecystokinin-8 (CCK-8), a prototype OATP1B3 substrate was utilized to assess
the transport activity of OATP1B3 WT and mutants, following transfection as described
previously.[73] Briefly, MDCKII and HEK293 cells were seeded onto a 12 well plate (2.5 x
105 cells/well). After 24 h, the cells were transfected with OATP1B3 WT, its mutants and
empty vector. The experiment was performed 24 h after transfection. Following three
washes with pre-warmed Opti-MEM (Invitrogen), the uptake was initiated by adding 0.5
mL of Optim-MEM containing [3H]-CCK-8 (0.01 μM). To further validate the involvement
of OATP1B3 in the uptake of CCK-8, rifampin (an OATP1B3 inhibitor, 100 μM) [73] was
added in an additional set of wells. The uptake was stopped at 5 min (verified to be in the
linear range from a separate time-dependent uptake experiment) by rinsing the cells three
times with ice-cold PBS. The cells were lysed with 0.5 N NaOH on a shaker for 30 min.
The lysates were then neutralized with 2.5N HCl and 250 µL of lysate was added to 3 mL
of LSC cocktail. Radioactivity was measured using TriCarb LSC counter (Perkin-Elmer).
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The uptake of [3H] CCK-8 in each well was normalized to the protein amount measured
using the BCA protein assay kit (Pierce).
5.2.7 Cell surface biotinylation
In order to investigate the subcellular localization of OATP1B3 WT and mutants, surface
biotinylation assays were performed in HEK293 cells, following transient transfection
similar to the protocol described previously [73]. Briefly, cells were rinsed with ice-cold
PBS-Ca2+/Mg2+ and then treated with the membrane impermeable biotinylating agent (1.5
mg/mL sulfo-NHS-SS-biotin, Pierce) at 4⁰C for 1h. Later, the cells were washed three
times with ice-cold PBS-Ca2+/Mg2+ containing 100 mM glycine and incubated at 4⁰C for 20
min to remove the excess biotinylating agent. The cells were then lysed in lysis buffer
containing protease inhibitors (Roche). After centrifugation, streptavidin agarose beads
(Pierce) were incubated with cell lysates at 4⁰C for 1 h. The beads were separated from
the supernatant (cytoplasmic fraction) by centrifugation. The beads were washed three
times with ice-cold lysis buffer and incubated in Laemmli buffer for 30 min to release the
biotinylated (membrane) fraction.
5.2.8 Immunofluorescence assays
HEK293 cells were seeded onto 4 chamber culture slides (BD Biosciences). After twentyfour hours, cells were transfected with myc-tagged OATP1B3 WT, Δ11, Δ23, Δ28
truncation mutants and point mutants at the putative β-turn tetrapeptide site as described
above. Twenty four hours after transfection, the cells were fixed with 4%
paraformaldehyde in ice-cold PBS for 30 min. Later, the cells were permeabilized with
PBS containing 0.3% Triton X-100 for 20 min at room temperature and blocked using PBS
containing for 1 h at room temperature. The cells were then incubated with a primary
antibody against the Myc tag (Cell Signaling), followed by a secondary antibody
conjugated to Alexa Fluor 488 (Invitrogen). Nuclear DNA was stained using DAPI (Vector
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Laboratories Inc.). The immunofluorescence signal was detected using a Nikon (Eclipse
Ti-U) fluorescence microscope or Leica Confocal microscope (Leica TCS SP5).
5.2.9 Statistical Analyses
The results are presented as mean ± SD. In the transport studies, the statistical
significance between groups was determined using one-way ANOVA followed by
Newman-Kuels test. P values of ≤0.05 were considered to be statistically significant. The
calculations were performed using GraphPad Prism 5.04.
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5.3 RESULTS
5.3.1 Identification of putative amino acid signal sequences at the N-terminus of OATP1B3
WT involved in its plasma membrane trafficking
To probe the signal sequence(s) important for the plasma membrane localization of
OATP1B3, we performed in-silico analyses for the N-terminus of OATP1B3. Using various
prediction algorithms such as PROSITE, CLOUDES, and BetaTPred, we identified several
putative consensus hits that may be involved in cellular signaling (Fig 5.1A). Based on the
location of predicted consensus hits on the OATP1B3, we prepared three myc-tag-fused
truncation mutants with the N-terminus of OATP1B3 incrementally deleted (represented
as Δ11, Δ23, Δ28, respectively, Fig. 5.1B).
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Figure 5. 1 In silico analyses of N-terminus of OATP1B3 wild-type (WT)
(A) Identification of putative amino acid motifs likely to be involved in cellular trafficking
and localization signal of OATP1B3 by utilizing in silico algorithms. (B) Schematic
representation of the prepared truncation mutants (myc-tag fused at C-terminus); deletion
mutants of 11, 23 and 28 amino acids were represented as Δ11, Δ23 and Δ28,
respectively.
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5.3.2 Truncation of N-terminus leads to reduced plasma membrane localization of
OATP1B3
Immunofluorescence imaging analyses indicated that the deletion of the first 11 amino
acids at the N-terminus does not affect the plasma membrane localization in OATP1B3
(Fig. 5.2A). However, further deletion of 23 and 28 amino acids led to substantially reduced
plasma membrane localization (Fig. 5.2A). Consistent results were also obtained using
surface fractionation assays. While the truncation of the first 11 amino acids of OATP1B3
does not affect its surface expression level, the deletions of 23 and 28 amino acids at Nterminus result in the substantial reduction of OATP1B3 in the surface membrane fraction
as well as in total lysates (Fig. 5.2B). These results suggest that important motif(s)
regulating the surface localization and expression level of OATP1B3 may be present
between amino acids 12 and 23.
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Figure 5. 2 Comparison of N-terminus truncation mutants of OATP1B3 WT
(A) Confocal microscopy analyses revealed that truncation of 23 and 28 amino acids at
N-terminus of OATP1B3 led to reduced plasma membrane localization compared to
OATP1B3 WT. (B) Immunoblotting analyses indicated that OATP1B3 Δ23 and Δ28
mutants have much reduced protein expression levels in surface and total fractions
compared to OATP1B3 WT.
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5.3.3 Comparison of point mutants at positively charged and putative phosphorylation
sites located between amino acids 12 and 23 of OATP1B3
To further identify the important residues between amino acids 12 to 23, we utilized the
SDM approach. Lysine and arginine residues were individually mutated to alanine at
positions 18, 19, 20, 22 and 23 (represented as K18A, K19A, K20A, R22A and R23A
respectively) and transiently expressed in HEK293 cells. The results from immunoblotting
analyses of fractionated samples indicated that mutating the lysine or arginine sites at
these positions did not affect the total protein expression or the surface levels as compared
to OATP1B3 WT (Fig. 5.3). Similarly, mutating the serine sites at position 13, 15 and 16
(represented as S13A, S15A and S16A) did not impact total protein levels or surface
expression as compared to OATP1B3 WT (Fig. 5.4). These findings suggest that lysine
or serine residues at the amino positions 12 to 23 may not be important in regulating the
expression or surface localization of OATP1B3.
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Figure 5.3 Comparison of point mutants of positively charged lysine or arginine
residues located at the N-terminal region of OATP1B3 wildtype
Immunoblotting analyses reveal that the total and surface expression levels of point
mutants at the N-terminal lysine and arginine residues are not substantially different from
those of the OATP1B3 WT.
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Figure 5. 4 Comparison of point mutants of putative phosphorylation sites located
at the N-terminal region of OATP1B3 wildtype
Immunoblotting analyses reveal that the total and surface expression levels of point
mutants at the N-terminal serine residues are not substantially different from those of the
OATP1B3 WT.
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5.3.4 Comparison of point mutants at the putative β-turn forming tetrapeptide site between
amino acids 12 and 23 of OATP1B3
As a next step in interrogating the sequence(s) important in regulating OATP1B3
trafficking, we analyzed the β-turn forming propensity (Δ score) of the OATP1B3 WT
sequence (14ASSE17) as well as mutants

14

ASaE17 and

14

ASaa17 (Fig. 5.5A). These

mutated constructs were prepared by SDM and transiently transfected in HEK293 cells
along with GFP (included to ensure comparable transfection efficiencies). The results from
cell surface fractionation assays indicated that compared to OATP1B3 WT, the

14

ASaa17

mutant displays a significantly reduced expression level in the total lysate as well as in the
surface membrane fraction (Fig. 5.5B). As expected, the

14

ASaa17 mutant was found to

have a much reduced uptake of 3H-CCK-8 compared to OATP1B3 WT.
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Figure 5.5 Comparison of point mutants at putative β-turn forming tetrapeptide sites
at the N-terminus of OATP1B3
(A) In silico calculation using Chou algorithm revealed that the N-terminus of OATP1B3
WT contains a putative tetrapeptide (14ASSE17) with the highest Δ-score and propensity to
form a β-turn. Sequential mutation of this position leads to substantial reduction in Δ-score.
(B) Immunoblotting results showing that the 14ASaa17 mutant at the putative β-turn forming
sequence has lower total and surface expression levels than OATP1B3 WT. Na+/K+
ATPase was used as an internal control to ensure comparable surface membrane protein
loading. (C) Comparison of cellular uptake of 3H-CCK-8 in cells expressing

14

ASaa17

mutant and OATP1B3 WT in the presence and absence of rifampin (the inhibitor of
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OATP1B3 transport activity). Data are represented as percentiles relative to the empty
vector controls. Data are expressed as mean ± SD.
5.4 DISCUSSION
While the functional significance of OATP1B3 in hepatic drug disposition and overall drug
response has been extensively investigated, little has been known about its mechanisms
of expression and membrane localization. The findings from our current study for the first
time identified the motifs at the N-terminus of OATP1B3 that may play a key role in
regulating the membrane localization and expression of OATP1B3. Using sequential
truncation and point mutation approaches, we report that the amino acid region between
12 to 23, specifically 14ASSE17 with a high β-turn forming potential may be important. Our
findings may provide important starting points in understanding the molecular processes
of regulating intracellular trafficking of OATP1B3 and potentially other related members of
the OATP family.
For certain OATP family members, the PDZ consensus sequences have been reported to
play a role in regulating their membrane trafficking. However, no PDZ consensus
sequences have been predicted for OATP1B3 and other members of the OATP1 family
[167, 168]. Similar to our results supporting the involvement of a β-turn forming
tetrapeptide (14ASSE17) in the membrane trafficking of OATP1B3, other studies have
implicated the role of β-turn forming tetrapeptides in the membrane localization of
transporters such as rat ileal apical sodium-dependent bile acid transporter (Asbt), human
sodium-dependent vitamin C transporter (hSVCT1) and the human concentrative
nucleoside transporter 3 (hCNT3) [113, 169-171]. In these previous investigations,
disruption of the β-turn forming potential by SDM or deletion resulted in partial to complete
mislocalization of these transporters [113, 169-171]. The prediction of the β-turn structures
is currently dependent on mathematical calculation, partly due to the lack of state-of-art
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technologies that can provide structural resolution. While the N-terminal β-turn structure
that we propose in the current report remains to be structurally verified, our results do
provide an interesting lead for further investigations on potential partnering proteins that
may interact with OATP1B3 at the N-terminal region identified to form a β-turn.
Our results obtained from the point mutations at lysine, arginine and serine residues at the
N-terminal region of OATP1B3 appear to indicate that these residues are not critically
involved in the regulation of membrane trafficking or expression levels of OATP1B3 (Figs.
5.3 and 5.4). Interestingly, a recent report by Powell et al. indicated that OATP1B3mediated transport activity can be impaired by protein kinase C (PKC) activation [172].
However, it needs to be investigated whether this effect occurs via direct phosphorylation
of OATP1B3 and phosphorylation of other intermediary proteins. OATP2B1 is also
reported to undergo PKC-mediated internalization [173]. However, specific motifs involved
in the PKC-mediated internalization of OATP2B1 have not been identified.
In our current study, we observed that the N-terminal region of OATP1B3 may play a role
in regulating not only protein localization, but also the expression level of OATP1B3. It is
plausible that the processes regulating the localization and stability of OATP1B3 may be
operating co-dependently. For instance, the ABCB11 gene encoding bile salt export pump
(BSEP) harbors naturally occurring mutations causing progressive familial intrahepatic
cholestasis type 2 (PFIC2) [174]. These mutations (E297G and D482G) in BSEP led to
the impairment of its surface trafficking as well as the reduced expression level. When the
surface trafficking of BSEP was in part restored by 4-phenylbutyrate treatment, the authors
observed an increased expression level of BSEP at the surface fraction and total lysates
as well as the restoration of its transport activity [175].
In summary, we identified for the first time the N-terminal motifs of OATP1B3 important in
regulating its expression and membrane localization. In particular, the amino acids within
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a putative β-turn-forming tetrapeptide appear to be important.

Our findings provide

important starting points in further mechanistic investigations for the regulation of
OATP1B3 trafficking and expression, potentially applicable to other OATP family
members.

Copyright © Nilay Thakkar 2015
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Chapter 6

Conclusions and future directions
(Each chapter of this thesis contains its own conclusion section and therefore this
chapter is intended to provide a brief overview of the findings from this work.)
The results from this thesis work showed that colon and pancreatic cancer cells express
a cancer-specific variant of OATP1B3 (csOATP1B3), which differs from OATP1B3 WT at
its N-terminus (Chapter 3). Our findings also revealed that csOATP1B3 is regulated under
hypoxia by a mechanism involving hypoxia-inducible factor 1α (Chapter 4). These
findings add to the biological and mechanistic understanding of OATP1B3 in cancer. Our
results highlight that the molecular entities and regulatory mechanisms of ectopically
expressed proteins in cancer, including other OATP transporters may be dissimilar to
those detected in the nonmalignant tissues. Careful investigations at the molecular level
may lead to unexpected and exciting discoveries. We believe that these findings will help
us better design future studies to investigate the clinical significance of csOATP1B3 in
cancer patients. Some of the further investigations that may be designed are outlined
below.
It would be important to investigate the functional impact of csOATP1B3 on the behavior
of cancer cells. A previous report from our laboratory showed that OATP1B3 can confer
cell survival advantages in colon cancer cells by p53-dependent mechanisms [6].
Because the presence of csOATP1B3 was not known previously, this particular
experiment was carried out using cancer cells lines stably expressing the liver-type
OATP1B3 [6]. To verify whether csOATP1B3 also confers cancer cell survival
advantages in a similar manner to the liver-type OATP1B3, we carried out additional
experiments using siRNA-based knockdown. Our preliminary results showed that the
97

knockdown of csOATP1B3 enhances cell death in colon cancer cells treated with
oxaliplatin (data not shown). Further studies are required to elucidate the exact cellular
mechanisms that provide cancer cell survival through csOATP1B3.
Recently, there have been multiple reports on the detection of OATP1B3 in multiple types
of cancers [3, 5-7, 9, 67]. The majority of these reports utilized antibodies targeting the
C-terminus epitope of OATP1B3 [5, 6, 8]. In future studies, it would be informative to
obtain the expression patterns with antibodies targeting N-terminus of csOATP1B3 [73].
In addition, the investigation of intracellular locations of csOATP1B3 expressed in
cytoplasm may shed light on the functional studies of csOATP1B3 in cancer.
More importantly, it would be important to gain a better understanding of the clinical
significance of csOATP1B3. Future studies can be designed to examine the prognostic
and predictive values of csOATP1B3 expression in clinical tissue samples (by examining
any associations between the csOATP1B3 expression levels and clinical outcomes such
as survival and response/resistance to chemotherapy). Depending on the results from
these investigations, subsequent molecular investigations may be designed. For instance,
if csOATP1B3 expression would be associated with resistance to chemotherapy, further
investigations may be designed to interrogate the role of csOATP1B3 in conferring cell
survival advantages. In fact, a very recent report by Teft et al. [124] utilized this approach
and their findings suggest that OATP1B3 expression in cancer patients treated with
irinotecan-based chemotherapy are associated with shorter progression-free survivals.
Another potential aspect is to examine the expression of csOATP1B3 in hepatic cancer
tissues. The majority of research groups, including ours have reported the expression of
csOATP1B3 expression in cancers derived from non-hepatic tissues. It would be
interesting to determine whether csOATP1B3 is the predominant variant in other forms
of cancers, especially in hepatocellular carcinoma (HCC). A previous report by Vavricka
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et al. suggested that OATP1B3 mRNA levels were reduced in HCC [70]. Given that noncancerous hepatocytes express only OATP1B3 WT, it would be interesting to investigate
whether any csOATP1B3 is expressed in HCC and to compare the levels and functional
impact of OATP1B3 WT and csOATP1B3.
Following up on our observations with csOATP1B3 in cancer, our results showed that the
putative β-turn forming region at the N-terminus of OATP1B3 WT is important for its
membrane localization and expression (Chapter 5). These studies provide foremost
evidence regarding the role of the N-terminus in the expression and localization of
OATP1B3. Further studies may be designed to determine whether there are any
partnering proteins that interact with the N-terminal regions of OATP1B3 and play a role
in the plasma membrane localization of OATP1B3 WT. One of the initial investigations
could be aimed to understand the mechanisms of basolateral sorting of OATP1B3. Out of
the different partnering proteins, AP-1B (from the AP family of clathrin adaptor proteins) is
well-studied for its role in basolateral sorting [176]. Experiments that can be performed
may include quantitative live imaging after selective knockdown of clathrin in cell line
models expressing OATP1B3. These studies may assist in delineating whether the Golgi
complex and clathrin mediated sorting mechanisms exist for OATP1B3.
Given our investigations focused on OATP1B3, it would be interesting to examine if these
findings are applicable to the closely related family member, OATP1B1. Our in silico
analyses revealed that the amino acid region at the N-terminus of OATP1B1 displays the
highest propensity to form β-turn tetrapeptides. Studies may be designed to truncate the
N-terminus and specifically mutate the β-turn tetrapeptide region of OATP1B1.
Experiments including surface localization and transporter assays would demonstrate
whether our findings may be applicable to other members of the OATP family.
Copyright © Nilay Thakkar 2015
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